In Vitro Diagnostics Market by Product & Service (Kits, Instruments), Technology (Immunoassay, Hematology, Glucose Monitoring), Specimen (Blood), Site of Testing, Application (Endocrinology, Cardiology, Infectious Diseases) & Region- Global Forecast to 2030

icon1
USD 157.63 BN
MARKET SIZE, 2030
icon2
CAGR 7.6%
(2025-2030)
icon3
740
REPORT PAGES
icon4
882
MARKET TABLES

OVERVIEW

ivd-in-vitro-diagnostics-market Overview

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

The global in vitro diagnostics market, valued at US$101.05billion in 2024, stood at US$109.06 billion in 2025 and is projected to advance at a resilient CAGR of 7.6% from 2025 to 2030, culminating in a forecasted valuation of US$157.63 billion by the end of the period. Market growth is primarily fueled by the rising prevalence of chronic and infectious diseases, increasing demand for rapid and accurate diagnostic solutions, and the growing shift toward personalized medicine.

KEY TAKEAWAYS

  • By Region
    North America accounted for the largest share of 38.7% of the global IVD market in 2024.
  • By Product & Service
    By product & sevice, the reagents and kits segment held the largest share of 69.0% in 2024, driven by high testing volumes and recurring consumable demand.
  • By Technology
    By technology, the molecular diagnostics segment is projected to register the highest CAGR of 14.5% during the forecast period from 2025 to 2030.
  • By Specimen
    By specimen type, blood, serum, and plasma specimens represent the dominant category.
  • By Site of Testing
    By site of testing, the point-of-care testing is expected to be the fastest-growing segment market from 2025 to 2030.
  • By Application
    By application, the infectious disease segment accounted for the largest share in 2024.
  • By End User
    By end user, the hospitals & clinics segment constituted the largest end-user segment in 2024.
  • Competitive Landscape
    F. Hoffmann-La Roche, Danaher, and Abbott were identified as Star players in the global IVD market, backed by their broad diagnostic portfolios, strong market presence, and sustained leadership in high-value testing segments.
  • Competitive Landscape
    Devyser and Surmodics have distinguished themselves among SMEs by securing strong footholds in specialized diagnostic niches, underscoring their potential as emerging innovators within the IVD market.

The in vitro diagnostics (IVD) market is experiencing strong growth, driven by rising demand for early and accurate disease detection, the increasing use of molecular and point-of-care testing, and a greater focus on personalized medicine. Advances in PCR, immunoassays, and digital diagnostic platforms are enhancing clinical efficiency and faster decision-making. Strategic industry partnerships, expanding test volumes for infectious diseases, and growing healthcare investments are reshaping the market, accelerating the shift toward more accessible, rapid, and high-precision diagnostic solutions.

TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS

The impact on customers’ businesses in the IVD market is shaped by shifting diagnostic needs and rapid technological disruptions. Clinical laboratories, hospitals, home-care settings, blood banks, and public health labs are key users of IVD solutions, with accuracy, speed, and decentralization emerging as top priorities. The rise of molecular diagnostics, point-of-care testing, chemiluminescence assays, and next-generation sequencing is transforming workflow efficiency and expanding diagnostic capabilities. These advancements, combined with growing demand for infectious disease screening, oncology testing, and chronic disease monitoring, are fundamentally influencing operational models, revenue streams, and investment priorities across the healthcare ecosystem.

ivd-in-vitro-diagnostics-market Disruptions

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

MARKET DYNAMICS

Drivers
Impact
Level
  • Growing awareness of early disease diagnosis in emerging economies
  • Emergence of rapid PoC technologies and rising adoption of automated analyzers
RESTRAINTS
Impact
Level
  • Stringent regulatory requirements
  • High cost of diagnostic equipment
OPPORTUNITIES
Impact
Level
  • Improvements in immunoassay diagnostic technologies
  • Growth opportunities in developing countries
CHALLENGES
Impact
Level
  • Operational barriers
  • Data privacy and cybersecurity risks

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

Driver: Growing awareness of early disease diagnosis in emerging economies

The IVD market is benefiting significantly from rising awareness about early disease detection in emerging economies. Governments, healthcare providers, and public health bodies are increasingly promoting timely diagnostics to reduce treatment burdens and control infectious disease outbreaks. Expanded screening programs, improved healthcare access, and growing adoption of rapid tests and molecular technologies are accelerating market growth. As early diagnosis becomes a priority across developing regions, demand for reliable and affordable IVD solutions continues to rise.

Restraint: Stringent regulatory requirements

Stringent regulatory frameworks pose a significant restraint for the IVD market, creating delays in approvals and increasing compliance costs. Strict analytical validation, clinical evidence requirements, and post-market monitoring obligations extend development timelines. With evolving regulations such as IVDR in Europe and rigorous FDA standards, manufacturers face complex pathways that slow product launches and limit the speed of innovation.

Opportunity: Improvements in immunoassay diagnostic technologies

Rapid advancements in immunoassay technologies are opening substantial growth opportunities for the IVD industry. High-sensitivity assays, chemiluminescence platforms, multiplexing capabilities, and automation are significantly enhancing accuracy, throughput, and clinical utility. These innovations support improved detection of infectious diseases, oncology biomarkers, and chronic conditions. As laboratories modernize and shift toward automated workflows, demand for advanced immunoassay systems is rising, positioning this segment as a key driver of market expansion over the coming years.

Challenge: Operational barriers

Operational challenges including shortage of skilled laboratory staff, high instrument maintenance costs, and inconsistent infrastructure, continue to hinder IVD operations. Supply chain disruptions, variability in testing environments, and quality control issues can affect reliability and turnaround times. These barriers create inefficiencies for laboratories and healthcare providers, limiting optimal test performance and slowing broader adoption of advanced diagnostic technologies.

IN VITRO DIAGNOSTICS MARKET: GROWTH, SIZE, SHARE, AND TRENDS: COMMERCIAL USE CASES ACROSS INDUSTRIES

COMPANY USE CASE DESCRIPTION BENEFITS
Use of cobas 4800 and cobas 5800/6800/8800 molecular systems for high-throughput viral load testing in centralized clinical laboratories. High analytical accuracy, automated high-volume workflows, reduced turnaround time, and strong regulatory compliance supporting large-scale infectious disease testing.
Deployment of Alinity m analyzers for automated molecular detection of HIV, HBV, and HCV in medium- to high-throughput diagnostic settings. Faster sample-to-result time, minimal manual intervention, consistent assay performance, and enhanced workflow efficiency in infectious disease diagnostics.
Utilization of GeneXpert systems for rapid, cartridge-based molecular testing in decentralized and point-of-care environments. Quick results with minimal hands-on time, broad test menu across infectious diseases, high sensitivity, and strong suitability for low-resource or near-patient settings.
Use of the Atellica CI Analyzer for integrated clinical chemistry and immunoassay testing in hospital laboratories. Improved operational efficiency, faster turnaround times, streamlined sample management, and flexible scalability to support medium-throughput labs.
Application of the NextSeq 550Dx instrument for high-throughput next-generation sequencing (NGS) in oncology and genetic testing. High depth of sequencing, broad genomic coverage, faster analysis for complex mutations, and improved diagnostic precision in personalized medicine workflows.

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

MARKET ECOSYSTEM

The in vitro diagnostics (IVD) market ecosystem comprises suppliers such as Abacus ALS, manufacturers, and end users, including major healthcare institutions like the Cleveland Clinic, Johns Hopkins Medicine, and Unilabs. Suppliers provide critical reagents, consumables, and instrument components that feed into advanced diagnostic platforms used across laboratories. End users drive demand for accurate, rapid, and high-throughput testing to support clinical decision-making and population health management. Close collaboration across suppliers, manufacturers, and diagnostic service providers is essential to ensure innovation, regulatory compliance, and improved testing outcomes that shape the growth of the IVD market.

ivd-in-vitro-diagnostics-market Ecosystem

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

MARKET SEGMENTS

ivd-in-vitro-diagnostics-market Segments

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

In Vitro Diagnostics Market, By Product & Service

As of 2024, the reagents and kits segment held the largest share of the IVD market and is expected to continue leading through the forecast period due to recurring demand, high testing volumes, and essential use across all diagnostic platforms. Reagents form the backbone of molecular, immunoassay, and clinical chemistry workflows, ensuring consistent test accuracy and repeatability. The increasing adoption of automated analyzers, frequent infectious disease testing, and expanding screening programs further reinforce the dominance of reagents and kits in clinical laboratories and hospitals.

In Vitro Diagnostics Market, By Technology

The immunoassay segment dominates the IVD market, driven by its wide clinical applicability in infectious diseases, endocrinology, oncology, and the monitoring of chronic conditions. Immunoassays offer high specificity, rapid turnaround times, and compatibility with automated analyzers used in medium- to high-throughput laboratories. Continued advancements in chemiluminescence and multiplexing technologies, along with rising demand for high-sensitivity biomarker detection, are strengthening the leadership of immunoassays in clinical diagnostics worldwide.

In Vitro Diagnostics Market, By Specimen

In 2024, blood, serum, and plasma specimens represented the dominant specimen category within the IVD market due to their broad clinical relevance and compatibility with diverse diagnostic modalities, including molecular tests, immunoassays, and clinical chemistry. These specimen types remain critical for detecting infectious diseases, metabolic conditions, and oncology biomarkers. Their high clinical reliability, standardized handling, and widespread use across hospitals and central laboratories reinforce their continued market leadership.

In Vitro Diagnostics Market, By Site of Testing

As of 2024, the laboratory tests segment continues to dominate the IVD market, supported by established infrastructure, advanced analytical capabilities, and the high-volume demand for both routine and complex diagnostics. Central laboratories rely on automated analyzers, high-throughput systems, and integrated sample workflows to deliver accurate and timely results. Growing test complexity, increasing chronic disease monitoring, and the need for standardized clinical decision-making further strengthen the importance of centralized laboratory testing.

In Vitro Diagnostics Market, By Application

The infectious diseases segment accounted for the largest share of the IVD market in 2024, driven by persistent global demand for screening, diagnosis, and monitoring of viral and bacterial pathogens. High testing frequency for HIV, HBV, HCV, tuberculosis, and respiratory infections, coupled with outbreaks of emerging diseases, continues to boost the adoption of molecular diagnostics and immunoassays. The expansion of public health initiatives and rapid-test developments further reinforces the dominance of infectious disease diagnostics.

In Vitro Diagnostics Market, By End User

Hospitals and clinics constituted the largest end-user segment in the IVD market due to high patient inflow, comprehensive testing requirements, and integration of advanced diagnostic instruments within clinical workflows. These facilities rely heavily on molecular platforms, immunoassay analyzers, and rapid-testing systems to support emergency care, inpatient diagnosis, and chronic disease management. The increasing adoption of automated systems and a greater focus on clinical efficiency continue to strengthen hospitals’ central role in IVD testing.

REGION

North America to hold the largest share of the global in vitro diagnostics market during the forecast period

The North American market holds the largest share globally, supported by advanced healthcare infrastructure, high adoption of molecular and immunoassay technologies, and a strong emphasis on early disease detection. Widespread use of high-throughput analyzers across clinical laboratories and hospitals, coupled with significant investments in precision medicine and digital diagnostic platforms, strengthens the region’s leadership position. Growing demand for infectious disease testing, chronic disease monitoring, and rapid diagnostic workflows further reinforces North America’s dominance in the IVD market.

ivd-in-vitro-diagnostics-market Region

IN VITRO DIAGNOSTICS MARKET: GROWTH, SIZE, SHARE, AND TRENDS: COMPANY EVALUATION MATRIX

In the in vitro diagnostics market matrix, F. Hoffmann-La Roche Ltd (Star) leads with a strong market share and an extensive diagnostic portfolio, supported by its high-throughput molecular platforms, advanced immunoassay systems, and widespread adoption across major clinical laboratories. Sysmex Corporation (Emerging Leader) is gaining traction through its specialized hematology and coagulation analyzers, strengthening its position with innovative, automation-driven solutions. While Roche maintains dominance through scale, technological leadership, and broad clinical integration, Sysmex shows strong potential to advance toward the leaders’ quadrant as demand for high-precision, automated hematology testing continues to rise.

ivd-in-vitro-diagnostics-market Evaluation Metrics

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

KEY MARKET PLAYERS

MARKET SCOPE

REPORT METRIC DETAILS
Market Size in 2024 (Value) USD 101.05 Billion
Market Forecast in 2030 (Value) USD 157.63 Billion
Growth Rate CAGR of 7.6% from 2025-2030
Years Considered 2022-2030
Base Year 2024
Forecast Period 2025-2030
Units Considered Value (USD Million/Billion), Volume (Billion)
Report Coverage Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments Covered
  • By Product:
    • Reagents & Kits
    • Instruments
    • Data Management Software & Services
  • By Technology:
    • Immunoassays
    • Clinical Chemistry
    • Molecular Diagnostics
    • Glucose Monitoring
    • Hematology
    • Microbiology
    • Coagulation & Hemostasis
    • Blood Gas Analyzers
    • Urinalysis
    • Chromatography & Mass Spectrometry
  • By Specimen:
    • Blood
    • Serum
    • Plasma
    • Saliva
    • Urine
    • Other Specimens
  • By Site of Testing:
    • Laboratory Tests
    • Point-of-Care Tests
  • By Application:
    • Infectious Diseases
    • Oncology
    • Endocrinology
    • Cardiology
    • Blood Screening
    • Genetic Testing
    • Autoimmune Diseases
    • Allergy Diagnostics
    • Drug Monitoring & Testing
    • Bone & Mineral Disorders
    • Coagulation Testing
    • Blood Group Typing
    • Other Applications
  • By End User:
    • Hospitals & Clinics
    • Clinical Laboratories
    • Blood Banks
    • Home Care Settings
    • Pharmaceutical & Biotechnology Companies
    • Academic Institutes
    • Other End Users
Regions Covered North America, Europe, Asia Pacific, Latin America, Middle East & Africa, GCC Countries

WHAT IS IN IT FOR YOU: IN VITRO DIAGNOSTICS MARKET: GROWTH, SIZE, SHARE, AND TRENDS REPORT CONTENT GUIDE

ivd-in-vitro-diagnostics-market Content Guide

RECENT DEVELOPMENTS

  • February 2025 : F. Hoffmann-La Roche Ltd introduced a novel class of next-generation sequencing (NGS) powered by its proprietary Sequencing by Expansion (SBX) technology, aimed at enhancing sequencing accuracy, efficiency, and scalability.
  • November 2024 : F. Hoffmann-La Roche Ltd has entered into a definitive merger agreement to acquire Poseida Therapeutics, Inc., a publicly traded clinical-stage biopharmaceutical company specializing in donor-derived CAR-T cell therapies, strengthening its cell and gene therapy portfolio.
  • July 2024 : Beckman Coulter, Inc. and Fujirebio collaborated to identify novel blood-based biomarkers and further develop existing biomarkers for tau pathology in Alzheimer's disease.

 

Table of Contents

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE
PAGE NO
1
INTRODUCTION
 
 
 
 
 
57
2
RESEARCH METHODOLOGY
 
 
 
 
 
62
3
EXECUTIVE SUMMARY
 
 
 
 
 
75
4
PREMIUM INSIGHTS
 
 
 
 
 
82
5
MARKET OVERVIEW
Emerging markets and tech innovations drive growth despite regulatory and cost challenges.
 
 
 
 
 
86
 
5.1
INTRODUCTION
 
 
 
 
 
 
5.2
MARKET DYNAMICS
 
 
 
 
 
 
 
5.2.1
DRIVERS
 
 
 
 
 
 
 
5.2.1.1
INCREASING GERIATRIC POPULATION AND SUBSEQUENT RISE IN CHRONIC DISEASES
 
 
 
 
 
 
5.2.1.2
GROWING AWARENESS OF EARLY DISEASE DIAGNOSIS IN EMERGING ECONOMIES
 
 
 
 
 
 
5.2.1.3
EMERGENCE OF RAPID POC TECHNOLOGIES AND RISING ADOPTION OF AUTOMATED ANALYZERS
 
 
 
 
 
 
5.2.1.4
GROWING PREFERENCE FOR PERSONALIZED MEDICINES
 
 
 
 
 
5.2.2
RESTRAINTS
 
 
 
 
 
 
 
5.2.2.1
UNFAVORABLE REIMBURSEMENT SCENARIO
 
 
 
 
 
 
5.2.2.2
STRINGENT REGULATORY REQUIREMENTS
 
 
 
 
 
 
5.2.2.3
HIGH COST OF DIAGNOSTIC EQUIPMENT
 
 
 
 
 
5.2.3
OPPORTUNITIES
 
 
 
 
 
 
 
5.2.3.1
INTRODUCTION OF DISEASE-SPECIFIC BIOMARKERS AND TESTS
 
 
 
 
 
 
5.2.3.2
INCREASING SIGNIFICANCE OF COMPANION DIAGNOSTICS
 
 
 
 
 
 
5.2.3.3
GROWTH OPPORTUNITIES IN DEVELOPING COUNTRIES
 
 
 
 
 
 
5.2.3.4
IMPROVEMENTS IN IMMUNOASSAY DIAGNOSTIC TECHNOLOGIES
 
 
 
 
 
 
5.2.3.5
DIGITALIZATION TREND
 
 
 
 
 
5.2.4
CHALLENGES
 
 
 
 
 
 
 
5.2.4.1
OPERATIONAL BARRIERS
 
 
 
 
 
 
5.2.4.2
DATA PRIVACY AND CYBERSECURITY RISKS
 
 
 
 
5.3
TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
 
 
 
 
 
 
5.4
PRICING ANALYSIS
 
 
 
 
 
 
 
 
5.4.1
AVERAGE SELLING PRICE TREND, BY KEY PLAYER
 
 
 
 
 
 
5.4.2
AVERAGE SELLING PRICE TREND, BY REGION
 
 
 
 
 
 
5.4.3
AVERAGE SELLING PRICE TREND, BY PRODUCT
 
 
 
 
 
5.5
VALUE CHAIN ANALYSIS
 
 
 
 
 
 
 
 
5.5.1
RESEARCH & DEVELOPMENT
 
 
 
 
 
 
5.5.2
RAW MATERIAL SUPPLIERS
 
 
 
 
 
 
5.5.3
MANUFACTURING
 
 
 
 
 
 
5.5.4
DISTRIBUTION, MARKETING, AND SALES
 
 
 
 
 
 
5.5.5
RETAILERS
 
 
 
 
 
 
5.5.6
POST-SALES SERVICES
 
 
 
 
 
5.6
SUPPLY CHAIN ANALYSIS
 
 
 
 
 
 
 
 
5.6.1
PROMINENT COMPANIES
 
 
 
 
 
 
5.6.2
SMALL & MEDIUM-SIZED ENTERPRISES
 
 
 
 
 
 
5.6.3
END USERS
 
 
 
 
 
5.7
ECOSYSTEM ANALYSIS
 
 
 
 
 
 
 
5.8
INVESTMENT AND FUNDING SCENARIO
 
 
 
 
 
 
5.9
TECHNOLOGY ANALYSIS
 
 
 
 
 
 
 
5.9.1
KEY TECHNOLOGIES
 
 
 
 
 
 
5.9.2
COMPLEMENTARY TECHNOLOGIES
 
 
 
 
 
 
 
5.9.2.1
IMMUNOHISTOCHEMISTRY
 
 
 
 
5.10
PATENT ANALYSIS
 
 
 
 
 
 
 
5.11
TRADE ANALYSIS
 
 
 
 
 
 
 
 
5.11.1
IMPORT DATA FOR HS CODE 382200
 
 
 
 
 
 
5.11.2
EXPORT DATA FOR HS CODE 382200
 
 
 
 
 
5.12
KEY CONFERENCES AND EVENTS, 2025–2026
 
 
 
 
 
 
5.13
CASE STUDY ANALYSIS
 
 
 
 
 
 
 
5.13.1
CASE STUDY 1: LOCALIZED STRATEGY TO TAP MARKET POTENTIAL IN EUROPE
 
 
 
 
 
 
5.13.2
CASE STUDY 2: ENHANCED COMPANY FOOTPRINT IN COMPETITIVE INDIAN MARKET
 
 
 
 
 
 
5.13.3
CASE STUDY 3: CUSTOMER-CENTRIC DIFFERENTIATION FOR PRODUCT OPTIMIZATION AND PREMIUM PRICING
 
 
 
 
 
5.14
REGULATORY LANDSCAPE
 
 
 
 
 
 
 
5.14.1
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
5.15
REGULATORY FRAMEWORK
 
 
 
 
 
 
 
 
5.15.1
NORTH AMERICA
 
 
 
 
 
 
 
5.15.1.1
US
 
 
 
 
 
 
5.15.1.2
CANADA
 
 
 
 
 
5.15.2
EUROPE
 
 
 
 
 
 
5.15.3
ASIA PACIFIC
 
 
 
 
 
 
 
5.15.3.1
JAPAN
 
 
 
 
 
 
5.15.3.2
CHINA
 
 
 
 
 
 
5.15.3.3
INDIA
 
 
 
 
 
 
5.15.3.4
SOUTH KOREA
 
 
 
 
 
 
5.15.3.5
INDONESIA
 
 
 
 
 
 
5.15.3.6
RUSSIA
 
 
 
 
 
5.15.4
MIDDLE EAST & AFRICA
 
 
 
 
 
 
 
5.15.4.1
SAUDI ARABIA
 
 
 
 
 
 
5.15.4.2
AFRICA
 
 
 
 
 
5.15.5
LATIN AMERICA
 
 
 
 
 
 
 
5.15.5.1
MEXICO
 
 
 
 
 
 
5.15.5.2
BRAZIL
 
 
 
 
5.16
PORTER’S FIVE FORCES ANALYSIS
 
 
 
 
 
 
 
5.16.1
BARGAINING POWER OF SUPPLIERS
 
 
 
 
 
 
5.16.2
BARGAINING POWER OF BUYERS
 
 
 
 
 
 
5.16.3
THREAT OF NEW ENTRANTS
 
 
 
 
 
 
5.16.4
THREAT OF SUBSTITUTES
 
 
 
 
 
 
5.16.5
INTENSITY OF COMPETITIVE RIVALRY
 
 
 
 
 
5.17
KEY STAKEHOLDERS AND BUYING CRITERIA
 
 
 
 
 
 
 
 
5.17.1
KEY STAKEHOLDERS IN BUYING PROCESS
 
 
 
 
 
 
5.17.2
BUYING CRITERIA
 
 
 
 
 
5.18
RECENT POLICY CHANGES IN US MARKET AND THEIR POTENTIAL IMPACT ON APPROVAL PROCESS
 
 
 
 
 
 
5.19
INFLUENCE OF TARIFFS ON SUPPLY CHAIN RESILIENCE OF MEDTECH COMPANIES
 
 
 
 
 
 
5.20
GROWTH OF DECENTRALIZED TESTING VS. ADOPTION OF COST-EFFECTIVE CENTRALIZED TESTING
 
 
 
 
 
 
5.21
IMPACT OF AI/GENERATIVE AI ON IN VITRO DIAGNOSTICS MARKET
 
 
 
 
 
 
 
 
5.21.1
INTRODUCTION
 
 
 
 
 
 
5.21.2
MARKET POTENTIAL OF AI IN IVD DEVICES
 
 
 
 
 
 
5.21.3
AI USE CASES
 
 
 
 
 
 
5.21.4
KEY COMPANIES IMPLEMENTING AI
 
 
 
 
 
 
5.21.5
FUTURE OF GENERATIVE AI IN IN VITRO DIAGNOSTICS MARKET
 
 
 
 
6
IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 21 Data Tables
 
 
 
 
 
141
 
6.1
INTRODUCTION
 
 
 
 
 
 
6.2
REAGENTS & KITS
 
 
 
 
 
 
 
6.2.1
RISE IN TEST VOLUMES ACROSS CLINICAL LABS, HOSPITALS, AND POINT-OF-CARE SETTINGS TO AID GROWTH
 
 
 
 
 
6.3
INSTRUMENTS
 
 
 
 
 
 
 
6.3.1
GROWING TREND OF AUTOMATION TO DRIVE MARKET
 
 
 
 
 
6.4
DATA MANAGEMENT SOFTWARE & SERVICES
 
 
 
 
 
 
 
6.4.1
INCREASING SHIFT TOWARD CLOUD-BASED PLATFORMS AND REMOTE DATA ACCESS TO STIMULATE GROWTH
 
 
 
 
7
IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 198 Data Tables
 
 
 
 
 
156
 
7.1
INTRODUCTION
 
 
 
 
 
 
7.2
IMMUNOASSAYS
 
 
 
 
 
 
 
7.2.1
ENZYME-LINKED IMMUNOSORBENT ASSAYS (ELISA)
 
 
 
 
 
 
 
7.2.1.1
INCREASING USE OF IMMUNOASSAYS IN CANCER, INFECTIOUS DISEASE TESTING, AND THERAPEUTIC DRUG MONITORING TO AID GROWTH
 
 
 
 
 
7.2.2
CHEMILUMINESCENCE IMMUNOASSAYS
 
 
 
 
 
 
 
7.2.2.1
NEED FOR MINIMAL HUMAN INTERVENTION TO SUPPORT GROWTH
 
 
 
 
 
7.2.3
IMMUNOFLUORESCENCE ASSAYS
 
 
 
 
 
 
 
7.2.3.1
GROWING INTRODUCTION OF INNOVATIVE DIAGNOSTIC PLATFORMS TO DRIVE MARKET
 
 
 
 
 
7.2.4
RAPID TESTS
 
 
 
 
 
 
 
7.2.4.1
NEED FOR RAPID DIAGNOSTIC TESTS TO EXPEDITE GROWTH
 
 
 
 
 
7.2.5
ENZYME-LINKED IMMUNOSPOT ASSAYS (ELISPOT)
 
 
 
 
 
 
 
7.2.5.1
NEED FOR EARLY DETECTION AND MONITORING OF IMMUNE-RELATED DISORDERS TO AMPLIFY GROWTH
 
 
 
 
 
7.2.6
WESTERN BLOTTING
 
 
 
 
 
 
 
7.2.6.1
INCREASING FOCUS ON BIOMARKER DISCOVERY AND PERSONALIZED TREATMENT TO ADVANCE GROWTH
 
 
 
 
 
7.2.7
OTHER IMMUNOASSAY TECHNOLOGIES
 
 
 
 
 
7.3
CLINICAL CHEMISTRY
 
 
 
 
 
 
 
7.3.1
BASIC METABOLIC PANELS
 
 
 
 
 
 
 
7.3.1.1
INCREASING INCIDENCE OF DIABETES, KIDNEY DISORDERS, AND HYPERTENSION TO PROMOTE GROWTH
 
 
 
 
 
7.3.2
LIVER PANELS
 
 
 
 
 
 
 
7.3.2.1
RISING PREVALENCE OF CIRRHOSIS AND VIRAL HEPATITIS TO FOSTER GROWTH
 
 
 
 
 
7.3.3
RENAL PROFILES
 
 
 
 
 
 
 
7.3.3.1
GROWING AWARENESS FOR PREVENTIVE HEALTH CHECK-UPS TO BOOST MARKET
 
 
 
 
 
7.3.4
LIPID PROFILES
 
 
 
 
 
 
 
7.3.4.1
RISING PREVALENCE OF OBESITY TO ACCELERATE GROWTH
 
 
 
 
 
7.3.5
THYROID FUNCTION PROFILES
 
 
 
 
 
 
 
7.3.5.1
HIGH INCIDENCE OF THYROID-RELATED DISORDERS TO SUPPORT GROWTH
 
 
 
 
 
7.3.6
ELECTROLYTE PANELS
 
 
 
 
 
 
 
7.3.6.1
GROWING SHIFT TOWARD HOME CARE AND REMOTE PATIENT MONITORING TO FUEL MARKET
 
 
 
 
 
7.3.7
SPECIALTY CHEMICAL TESTS
 
 
 
 
 
 
 
7.3.7.1
RISING DEMAND FOR SPECIALIZED TESTS TO CONTRIBUTE TO GROWTH
 
 
 
 
7.4
MOLECULAR DIAGNOSTICS
 
 
 
 
 
 
 
7.4.1
POLYMERASE CHAIN REACTION
 
 
 
 
 
 
 
7.4.1.1
HIGH ACCURACY AND SPEED IN DETECTING PATHOGENS TO AID GROWTH
 
 
 
 
 
7.4.2
ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY
 
 
 
 
 
 
 
7.4.2.1
GROWING FOCUS ON RAPID, ONSITE MOLECULAR DIAGNOSTICS TO PROPEL MARKET
 
 
 
 
 
7.4.3
DNA SEQUENCING & NEXT-GENERATION SEQUENCING
 
 
 
 
 
 
 
7.4.3.1
GROWING APPLICATIONS IN RESEARCH, DRUG DISCOVERY, AND MOLECULAR DIAGNOSTICS TO BOOST MARKET
 
 
 
 
 
7.4.4
IN SITU HYBRIDIZATION
 
 
 
 
 
 
 
7.4.4.1
RISING PREVALENCE OF CANCER AND GENETIC DISORDERS TO ASSIST GROWTH
 
 
 
 
 
7.4.5
DNA MICROARRAYS
 
 
 
 
 
 
 
7.4.5.1
HIGH RESOLUTION AND THROUGHPUT CAPABILITIES TO FAVOR GROWTH
 
 
 
 
 
7.4.6
OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES
 
 
 
 
 
7.5
GLUCOSE MONITORING
 
 
 
 
 
 
 
7.5.1
ONGOING TECHNOLOGICAL ADVANCEMENTS IN BLOOD GLUCOSE SELF-MONITORING DEVICES TO AID GROWTH
 
 
 
 
 
7.6
HEMATOLOGY
 
 
 
 
 
 
 
7.6.1
GROWING FOCUS ON STEM CELL RESEARCH TO BOOST MARKET
 
 
 
 
 
7.7
MICROBIOLOGY
 
 
 
 
 
 
 
7.7.1
RISING PREVALENCE OF MICROBIAL INFECTIONS TO SUSTAIN GROWTH
 
 
 
 
 
7.8
COAGULATION & HEMOSTASIS
 
 
 
 
 
 
 
7.8.1
GROWING CASES OF PULMONARY EMBOLISM, HEMOPHILIA, LIVER DISEASES TO DRIVE MARKET
 
 
 
 
 
7.9
BLOOD GAS ANALYZERS
 
 
 
 
 
 
 
7.9.1
GROWING SURGICAL INTERVENTIONS AND RISE IN ELDERLY POPULATION TO FUEL MARKET
 
 
 
 
 
7.10
URINALYSIS
 
 
 
 
 
 
 
7.10.1
RISING INCIDENCE OF URINARY TRACT INFECTIONS TO SUPPORT GROWTH
 
 
 
 
 
7.11
CHROMATOGRAPHY & MASS SPECTROMETRY
 
 
 
 
 
 
 
7.11.1
INCREASING APPLICATIONS IN DISEASE SCREENING AND DIAGNOSTICS TO AID GROWTH
 
 
 
 
8
IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 27 Data Tables
 
 
 
 
 
270
 
8.1
INTRODUCTION
 
 
 
 
 
 
8.2
BLOOD, SERUM, AND PLASMA SPECIMENS
 
 
 
 
 
 
 
8.2.1
GROWING SHIFT TOWARD DECENTRALIZED TESTING TO PROPEL MARKET
 
 
 
 
 
8.3
SALIVA SPECIMENS
 
 
 
 
 
 
 
8.3.1
GROWING ADVANCEMENTS IN MOLECULAR DIAGNOSTICS TO BOOST MARKET
 
 
 
 
 
8.4
URINE SPECIMENS
 
 
 
 
 
 
 
8.4.1
RISING INCIDENCE OF URINARY TRACT INFECTIONS TO ACCELERATE GROWTH
 
 
 
 
 
8.5
OTHER SPECIMENS
 
 
 
 
 
9
IN VITRO DIAGNOSTICS MARKET, BY SITE OF TESTING
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 15 Data Tables
 
 
 
 
 
286
 
9.1
INTRODUCTION
 
 
 
 
 
 
9.2
LABORATORY TESTS
 
 
 
 
 
 
 
9.2.1
INCREASING FOCUS ON EARLY AND ACCURATE DISEASE DETECTION TO ENCOURAGE GROWTH
 
 
 
 
 
9.3
POINT-OF-CARE TESTS
 
 
 
 
 
 
 
9.3.1
RISING DEMAND FOR DECENTRALIZED HEALTHCARE TO CONTRIBUTE TO GROWTH
 
 
 
 
10
IN VITRO DIAGNOSTICS MARKET, BY APPLICATION
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 84 Data Tables
 
 
 
 
 
299
 
10.1
INTRODUCTION
 
 
 
 
 
 
10.2
INFECTIOUS DISEASES
 
 
 
 
 
 
 
10.2.1
INCREASING PREVALENCE OF VIRAL, BACTERIAL, AND PARASITIC INFECTIONS TO PROMOTE GROWTH
 
 
 
 
 
10.3
ONCOLOGY
 
 
 
 
 
 
 
10.3.1
RISING GLOBAL BURDEN OF CANCER TO EXPEDITE GROWTH
 
 
 
 
 
10.4
ENDOCRINOLOGY
 
 
 
 
 
 
 
10.4.1
INCREASING PREVALENCE OF DIABETES AND THYROID-RELATED DISORDERS TO BOLSTER GROWTH
 
 
 
 
 
10.5
CARDIOLOGY
 
 
 
 
 
 
 
10.5.1
GROWING USE OF IMMUNOASSAYS IN CARDIOVASCULAR DISEASE DETECTION TO DRIVE MARKET
 
 
 
 
 
10.6
BLOOD SCREENING
 
 
 
 
 
 
 
10.6.1
RISING INCIDENCE OF HIV AND SYPHILIS TO SUPPORT GROWTH
 
 
 
 
 
10.7
GENETIC TESTING
 
 
 
 
 
 
 
10.7.1
INCREASING CLINICAL UTILITY OF GENETIC TESTS ACROSS ONCOLOGY, RARE DISEASES, AND REPRODUCTIVE HEALTH TO FOSTER GROWTH
 
 
 
 
 
10.8
AUTOIMMUNE DISEASES
 
 
 
 
 
 
 
10.8.1
RISE IN AUTOIMMUNE CONDITIONS GLOBALLY TO FACILITATE GROWTH
 
 
 
 
 
10.9
ALLERGY DIAGNOSTICS
 
 
 
 
 
 
 
10.9.1
INCREASING AWARENESS ABOUT ALLERGIES TO AMPLIFY GROWTH
 
 
 
 
 
10.10
DRUG MONITORING & TESTING
 
 
 
 
 
 
 
10.10.1
INCREASING ILLICIT DRUG CONSUMPTION TO SUSTAIN GROWTH
 
 
 
 
 
10.11
BONE & MINERAL DISORDERS
 
 
 
 
 
 
 
10.11.1
RISING CASES OF OSTEOPOROSIS TO FUEL MARKET
 
 
 
 
 
10.12
COAGULATION TESTING
 
 
 
 
 
 
 
10.12.1
INCREASING PREVALENCE OF HEMOPHILIA TO ADVANCE GROWTH
 
 
 
 
 
10.13
BLOOD GROUP TYPING
 
 
 
 
 
 
 
10.13.1
RISING NUMBER OF SURGICAL PROCEDURES TO SPEED UP GROWTH
 
 
 
 
 
10.14
OTHER APPLICATIONS
 
 
 
 
 
11
IN VITRO DIAGNOSTICS MARKET, BY END USER
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 56 Data Tables
 
 
 
 
 
349
 
11.1
INTRODUCTION
 
 
 
 
 
 
11.2
HOSPITALS & CLINICS
 
 
 
 
 
 
 
11.2.1
EXPANDING HEALTHCARE INFRASTRUCTURE TO SPEED UP GROWTH
 
 
 
 
 
11.3
CLINICAL LABORATORIES
 
 
 
 
 
 
 
11.3.1
LARGE REFERENCE LABORATORIES
 
 
 
 
 
 
 
11.3.1.1
GROWING TEST VOLUME AND COMPLEXITY OF DIAGNOSTIC TESTING TO PROPEL MARKET
 
 
 
 
 
11.3.2
SMALL AND MEDIUM-SIZED LABORATORIES
 
 
 
 
 
 
 
11.3.2.1
INCREASING SHIFT TOWARD COMMUNITY-BASED AND POINT-OF-CARE SETTINGS TO FOSTER GROWTH
 
 
 
 
11.4
BLOOD BANKS
 
 
 
 
 
 
 
11.4.1
NEED TO ADDRESS PUBLIC HEALTH AND SAFETY CHALLENGES TO AID GROWTH
 
 
 
 
 
11.5
HOME CARE SETTINGS
 
 
 
 
 
 
 
11.5.1
GROWING INCLINATION TOWARD SELF-DIAGNOSIS AND MONITORING TO BOOST MARKET
 
 
 
 
 
11.6
PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
 
 
 
 
 
 
 
11.6.1
INCREASING USE OF IVD PRODUCTS IN CLINICAL DRUG DEVELOPMENT AND COMPANION DIAGNOSTICS TO DRIVE MARKET
 
 
 
 
 
11.7
ACADEMIC INSTITUTES
 
 
 
 
 
 
 
11.7.1
RISING INDUSTRY-ACADEMIA COLLABORATIONS FOR PRODUCT DEVELOPMENT TO AUGMENT GROWTH
 
 
 
 
 
11.8
OTHER END USERS
 
 
 
 
 
12
IN VITRO DIAGNOSTICS MARKET, BY REGION
Comprehensive coverage of 8 Regions with country-level deep-dive of 18 Countries | 317 Data Tables.
 
 
 
 
 
382
 
12.1
INTRODUCTION
 
 
 
 
 
 
12.2
NORTH AMERICA
 
 
 
 
 
 
 
12.2.1
MACROECONOMIC OUTLOOK FOR NORTH AMERICA
 
 
 
 
 
 
12.2.2
US
 
 
 
 
 
 
 
12.2.2.1
ESTABLISHED REIMBURSEMENT FRAMEWORK AND FAVORABLE POLICIES FOR IVD PROVIDERS TO DRIVE MARKET
 
 
 
 
 
12.2.3
CANADA
 
 
 
 
 
 
 
12.2.3.1
FAVORABLE FUNDING INITIATIVES FOR EARLY DISEASE DIAGNOSIS TO FUEL MARKET
 
 
 
 
12.3
EUROPE
 
 
 
 
 
 
 
12.3.1
MACROECONOMIC OUTLOOK FOR EUROPE
 
 
 
 
 
 
12.3.2
GERMANY
 
 
 
 
 
 
 
12.3.2.1
INCREASING INVESTMENTS IN CLINICAL DIAGNOSTICS RESEARCH TO AID GROWTH
 
 
 
 
 
12.3.3
FRANCE
 
 
 
 
 
 
 
12.3.3.1
HIGH HEALTHCARE EXPENDITURE AND RISING INVESTMENTS IN GENOMIC MEDICINE TO DRIVE MARKET
 
 
 
 
 
12.3.4
UK
 
 
 
 
 
 
 
12.3.4.1
RISING ADOPTION OF GENOME-BASED TESTING TO ENCOURAGE GROWTH
 
 
 
 
 
12.3.5
ITALY
 
 
 
 
 
 
 
12.3.5.1
GROWING GERIATRIC POPULATION AND SUBSEQUENT RISE IN CHRONIC CONDITIONS TO BOOST MARKET
 
 
 
 
 
12.3.6
SPAIN
 
 
 
 
 
 
 
12.3.6.1
INCREASING ADOPTION OF TECHNOLOGICALLY ADVANCED IMMUNOASSAY SYSTEMS TO EXPEDITE GROWTH
 
 
 
 
 
12.3.7
RUSSIA
 
 
 
 
 
 
 
12.3.7.1
HIGH INCIDENCE OF RESPIRATORY INFECTIOUS DISEASES TO BOOST MARKET
 
 
 
 
 
12.3.8
SWITZERLAND
 
 
 
 
 
 
 
12.3.8.1
GROWING PREVALENCE OF CHRONIC DISEASES TO PROPEL MARKET
 
 
 
 
 
12.3.9
REST OF EUROPE
 
 
 
 
 
12.4
ASIA PACIFIC
 
 
 
 
 
 
 
12.4.1
MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
 
 
 
 
 
 
12.4.2
JAPAN
 
 
 
 
 
 
 
12.4.2.1
INCREASING RESEARCH INVESTMENTS FOR IMMUNOASSAYS TO ENCOURAGE GROWTH
 
 
 
 
 
12.4.3
CHINA
 
 
 
 
 
 
 
12.4.3.1
GROWING FOCUS ON PREVENTIVE CARE TO BOOST MARKET
 
 
 
 
 
12.4.4
INDIA
 
 
 
 
 
 
 
12.4.4.1
RISING INCIDENCE OF DIABETES AND CANCER TO AUGMENT GROWTH
 
 
 
 
 
12.4.5
SOUTH KOREA
 
 
 
 
 
 
 
12.4.5.1
RISING HEALTHCARE SPENDING FOR INNOVATIVE IVD TECHNOLOGIES TO AMPLIFY GROWTH
 
 
 
 
 
12.4.6
AUSTRALIA
 
 
 
 
 
 
 
12.4.6.1
INCREASING INCIDENCE OF CHRONIC DISEASES AND RISING BLOOD DONATIONS TO FUEL MARKET
 
 
 
 
 
12.4.7
SINGAPORE
 
 
 
 
 
 
 
12.4.7.1
RISING TECHNOLOGICAL ADVANCEMENTS AND AUTOMATION TO STIMULATE GROWTH
 
 
 
 
 
12.4.8
REST OF ASIA PACIFIC
 
 
 
 
 
12.5
LATIN AMERICA
 
 
 
 
 
 
 
12.5.1
MACROECONOMIC OUTLOOK FOR LATIN AMERICA
 
 
 
 
 
 
12.5.2
BRAZIL
 
 
 
 
 
 
 
12.5.2.1
RISING PREVALENCE OF DIABETES TO SUSTAIN GROWTH
 
 
 
 
 
12.5.3
MEXICO
 
 
 
 
 
 
 
12.5.3.1
GROWING ESTABLISHMENT OF CLINICAL LABORATORIES TO FUEL MARKET
 
 
 
 
 
12.5.4
REST OF LATIN AMERICA
 
 
 
 
 
12.6
MIDDLE EAST & AFRICA
 
 
 
 
 
 
 
12.6.1
GROWING FOCUS ON PRENATAL AND CANCER TESTING TO DRIVE MARKET
 
 
 
 
 
 
12.6.2
MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK
 
 
 
 
 
12.7
GCC COUNTRIES
 
 
 
 
 
 
 
12.7.1
GCC COUNTRIES: MACROECONOMIC OUTLOOK
 
 
 
 
 
 
12.7.2
SAUDI ARABIA
 
 
 
 
 
 
 
12.7.2.1
RISING GOVERNMENT HEALTHCARE EXPENDITURE TO BOOST MARKET
 
 
 
 
 
12.7.3
UAE
 
 
 
 
 
 
 
12.7.3.1
IMPROVEMENTS IN HEALTHCARE INFRASTRUCTURE TO SUPPORT GROWTH
 
 
 
 
 
12.7.4
OTHER GCC COUNTRIES
 
 
 
 
13
COMPETITIVE LANDSCAPE
Uncover strategic maneuvers and market positioning of industry leaders and rising startups.
 
 
 
 
 
561
 
13.1
OVERVIEW
 
 
 
 
 
 
13.2
KEY PLAYER STRATEGIES/RIGHT TO WIN
 
 
 
 
 
 
13.3
OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS
 
 
 
 
 
 
13.4
REVENUE ANALYSIS, 2022–2024
 
 
 
 
 
 
 
13.5
MARKET SHARE ANALYSIS, 2024
 
 
 
 
 
 
 
13.6
COMPANY VALUATION AND FINANCIAL METRICS
 
 
 
 
 
 
13.7
BRAND/PRODUCT COMPARISON
 
 
 
 
 
 
 
13.8
COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
 
 
 
 
 
 
 
 
13.8.1
STARS
 
 
 
 
 
 
13.8.2
EMERGING LEADERS
 
 
 
 
 
 
13.8.3
PERVASIVE PLAYERS
 
 
 
 
 
 
13.8.4
PARTICIPANTS
 
 
 
 
 
 
13.8.5
COMPANY FOOTPRINT: KEY PLAYERS, 2024
 
 
 
 
 
 
 
13.8.5.1
COMPANY FOOTPRINT
 
 
 
 
 
 
13.8.5.2
REGION FOOTPRINT
 
 
 
 
 
 
13.8.5.3
PRODUCT & SERVICE FOOTPRINT
 
 
 
 
 
 
13.8.5.4
TECHNOLOGY FOOTPRINT
 
 
 
 
 
 
13.8.5.5
END-USER FOOTPRINT
 
 
 
 
13.9
COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
 
 
 
 
 
 
 
 
13.9.1
PROGRESSIVE COMPANIES
 
 
 
 
 
 
13.9.2
RESPONSIVE COMPANIES
 
 
 
 
 
 
13.9.3
DYNAMIC COMPANIES
 
 
 
 
 
 
13.9.4
STARTING BLOCKS
 
 
 
 
 
 
13.9.5
COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
 
 
 
 
 
 
 
13.9.5.1
DETAILED LIST OF KEY STARTUPS/SMES
 
 
 
 
 
 
13.9.5.2
COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
 
 
 
 
13.10
COMPETITIVE SCENARIO
 
 
 
 
 
 
 
13.10.1
PRODUCT LAUNCHES AND APPROVALS
 
 
 
 
 
 
13.10.2
DEALS
 
 
 
 
 
 
13.10.3
EXPANSIONS
 
 
 
 
 
13.11
POTENTIAL FUTURISTIC STRATEGIES OF LEADING PLAYERS OPERATING IN IVD MARKET
 
 
 
 
 
 
 
13.11.1
PRODUCT LAUNCHES AND APPROVALS
 
 
 
 
 
 
13.11.2
DEALS
 
 
 
 
14
COMPANY PROFILES
In-depth Company Profiles of Leading Market Players with detailed Business Overview, Product and Service Portfolio, Recent Developments, and Unique Analyst Perspective (MnM View)
 
 
 
 
 
585
 
14.1
KEY PLAYERS
 
 
 
 
 
 
 
14.1.1
DANAHER
 
 
 
 
 
 
 
14.1.1.1
BUSINESS OVERVIEW
 
 
 
 
 
 
14.1.1.2
PRODUCTS/SERVICES OFFERED
 
 
 
 
 
 
14.1.1.3
RECENT DEVELOPMENTS
 
 
 
 
 
 
 
 
14.1.1.3.1
PRODUCT LAUNCHES AND APPROVALS
 
 
 
 
 
 
14.1.1.3.2
DEALS
 
 
 
 
 
 
14.1.1.3.3
EXPANSIONS
 
 
 
 
14.1.1.4
MNM VIEW
 
 
 
 
 
 
 
 
14.1.1.4.1
KEY STRENGTHS
 
 
 
 
 
 
14.1.1.4.2
STRATEGIC CHOICES
 
 
 
 
 
 
14.1.1.4.3
WEAKNESSES AND COMPETITIVE THREATS
 
 
 
14.1.2
F. HOFFMANN-LA ROCHE LTD
 
 
 
 
 
 
14.1.3
ABBOTT
 
 
 
 
 
 
14.1.4
SIEMENS HEALTHINEERS AG
 
 
 
 
 
 
14.1.5
THERMO FISHER SCIENTIFIC INC.
 
 
 
 
 
 
14.1.6
ILLUMINA, INC.
 
 
 
 
 
 
14.1.7
HOLOGIC, INC.
 
 
 
 
 
 
14.1.8
BIO-RAD LABORATORIES, INC.
 
 
 
 
 
 
14.1.9
BIOMÉRIEUX
 
 
 
 
 
 
14.1.10
SYSMEX CORPORATION
 
 
 
 
 
 
14.1.11
REVVITY
 
 
 
 
 
 
14.1.12
BECTON, DICKINSON AND COMPANY
 
 
 
 
 
 
14.1.13
AGILENT TECHNOLOGIES, INC.
 
 
 
 
 
 
14.1.14
QIAGEN
 
 
 
 
 
 
14.1.15
DIASORIN S.P.A.
 
 
 
 
 
 
14.1.16
GRIFOLS, S.A.
 
 
 
 
 
 
14.1.17
WERFEN
 
 
 
 
 
 
14.1.18
QUIDELORTHO CORPORATION
 
 
 
 
 
14.2
OTHER PLAYERS
 
 
 
 
 
 
 
14.2.1
DEVYSER
 
 
 
 
 
 
14.2.2
BIOSYNEX SA
 
 
 
 
 
 
14.2.3
SURMODICS, INC.
 
 
 
 
 
 
14.2.4
MENARINI SILICON BIOSYSTEMS
 
 
 
 
 
 
14.2.5
SPEEDX PTY. LTD.
 
 
 
 
 
 
14.2.6
GENSPEED BIOTECH GMBH
 
 
 
 
 
 
14.2.7
MERCK KGAA
 
 
 
 
 
 
14.2.8
CARIS LIFE SCIENCES
 
 
 
 
 
 
14.2.9
ARKRAY, INC.
 
 
 
 
 
 
14.2.10
ACCELERATE DIAGNOSTICS, INC.
 
 
 
 
 
 
14.2.11
CELLABS
 
 
 
 
 
 
14.2.12
J. MITRA & CO. PVT. LTD.
 
 
 
 
 
 
14.2.13
EPITOPE DIAGNOSTICS, INC.
 
 
 
 
 
 
14.2.14
BOSTER BIOLOGICAL TECHNOLOGY
 
 
 
 
 
 
14.2.15
ENZO BIOCHEM INC.
 
 
 
 
 
 
14.2.16
GENETIC SIGNATURES
 
 
 
 
 
 
14.2.17
SAVYON DIAGNOSTICS
 
 
 
 
 
 
14.2.18
TRIVITRON HEALTHCARE
 
 
 
 
 
 
14.2.19
MDXHEALTH
 
 
 
 
 
 
14.2.20
CREATIVE DIAGNOSTICS
 
 
 
 
 
 
14.2.21
INBIOS INTERNATIONAL, INC.
 
 
 
 
 
 
14.2.22
MACCURA BIOTECHNOLOGY CO., LTD.
 
 
 
 
 
 
14.2.23
LUYE LIFE SCIENCES GROUP
 
 
 
 
15
APPENDIX
 
 
 
 
 
728
 
15.1
DISCUSSION GUIDE
 
 
 
 
 
 
15.2
KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
 
 
 
 
 
 
15.3
CUSTOMIZATION OPTIONS
 
 
 
 
 
 
15.4
RELATED REPORTS
 
 
 
 
 
 
15.5
AUTHOR DETAILS
 
 
 
 
 
LIST OF TABLES
 
 
 
 
 
 
 
TABLE 1
IN VITRO DIAGNOSTICS MARKET: INCLUSIONS AND EXCLUSIONS
 
 
 
 
 
 
TABLE 2
IN VITRO DIAGNOSTICS MARKET: RISK ASSESSMENT
 
 
 
 
 
 
TABLE 3
ESTIMATED INCREASE IN GERIATRIC POPULATION, BY REGION, 2022−2050
 
 
 
 
 
 
TABLE 4
IN VITRO DIAGNOSTICS MARKET: PRODUCT LAUNCHES, 2022−2024
 
 
 
 
 
 
TABLE 5
APPLICATION OF CANCER BIOMARKERS IN CLINICAL PRACTICE
 
 
 
 
 
 
TABLE 6
RECENT DEVELOPMENTS IN IVD MARKET, 2021–2023
 
 
 
 
 
 
TABLE 7
AVERAGE SELLING PRICE TREND OF IVD PRODUCTS, BY KEY PLAYER, 2022–2024 (USD)
 
 
 
 
 
 
TABLE 8
AVERAGE SELLING PRICE TREND OF CLINICAL CHEMISTRY ANALYZERS, BY REGION, 2022–2024 (USD)
 
 
 
 
 
 
TABLE 9
AVERAGE SELLING PRICE TREND OF IVD PRODUCTS, BY TYPE, 2022–2024 (USD)
 
 
 
 
 
 
TABLE 10
IN VITRO DIAGNOSTICS MARKET: ROLE OF COMPANIES IN ECOSYSTEM
 
 
 
 
 
 
TABLE 11
IN VITRO DIAGNOSTICS MARKET: INNOVATIONS AND PATENT REGISTRATIONS, 2022−2024
 
 
 
 
 
 
TABLE 12
IMPORT DATA FOR HS CODE 382200, BY COUNTRY, 2019–2024 (USD MILLION)
 
 
 
 
 
 
TABLE 13
EXPORT DATA FOR HS CODE 382200, BY COUNTRY, 2019–2024 (USD MILLION)
 
 
 
 
 
 
TABLE 14
IN VITRO DIAGNOSTICS MARKET: KEY CONFERENCES AND EVENTS, 2025−2026
 
 
 
 
 
 
TABLE 15
NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
TABLE 16
EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
TABLE 17
ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
TABLE 18
LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
TABLE 19
REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
TABLE 20
US: CLASSIFICATION OF IVD DEVICES
 
 
 
 
 
 
TABLE 21
EUROPE: CLASSIFICATION OF IVD DEVICES
 
 
 
 
 
 
TABLE 22
JAPAN: CLASSIFICATION OF IVD REAGENTS IN JAPAN
 
 
 
 
 
 
TABLE 23
JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
 
 
 
 
 
 
TABLE 24
CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
 
 
 
 
 
 
TABLE 25
SOUTH KOREA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
 
 
 
 
 
 
TABLE 26
INDONESIA: REGISTRATION PROCESS FOR IVD DEVICES
 
 
 
 
 
 
TABLE 27
RUSSIA: CLASSIFICATION OF IVD DEVICES
 
 
 
 
 
 
TABLE 28
SAUDI ARABIA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
 
 
 
 
 
 
TABLE 29
MEXICO: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
 
 
 
 
 
 
TABLE 30
IN VITRO DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS
 
 
 
 
 
 
TABLE 31
INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF IVD PRODUCTS (%)
 
 
 
 
 
 
TABLE 32
KEY BUYING CRITERIA, BY PRODUCT & SERVICE
 
 
 
 
 
 
TABLE 33
US: OVERVIEW OF CERTAIN KEY CATEGORIES OF IVD DEVICES
 
 
 
 
 
 
TABLE 34
TARIFF RATES IMPOSED BY US, AS OF APRIL 2025
 
 
 
 
 
 
TABLE 35
COMPARATIVE ANALYSIS OF CENTRALIZED VS. DECENTRALIZED TESTING
 
 
 
 
 
 
TABLE 36
IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 37
IN VITRO DIAGNOSTICS MARKET FOR REAGENTS & KITS, BY REGION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 38
NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR REAGENTS & KITS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 39
EUROPE: IN VITRO DIAGNOSTICS MARKET FOR REAGENTS & KITS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 40
ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR REAGENTS & KITS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 41
LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR REAGENTS & KITS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 42
GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR REAGENTS & KITS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 43
KEY IVD INSTRUMENTS AVAILABLE WORLDWIDE
 
 
 
 
 
 
TABLE 44
IN VITRO DIAGNOSTICS MARKET FOR INSTRUMENTS, BY REGION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 45
NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 46
EUROPE: IN VITRO DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 47
ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 48
LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 49
GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 50
KEY DATA MANAGEMENT SOFTWARE SOLUTIONS AVAILABLE WORLDWIDE
 
 
 
 
 
 
TABLE 51
IN VITRO DIAGNOSTICS MARKET FOR DATA MANAGEMENT SOFTWARE & SERVICES, BY REGION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 52
NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR DATA MANAGEMENT SOFTWARE & SERVICES, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 53
EUROPE: IN VITRO DIAGNOSTICS MARKET FOR DATA MANAGEMENT SOFTWARE & SERVICES, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 54
ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR DATA MANAGEMENT SOFTWARE & SERVICES, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 55
LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR DATA MANAGEMENT SOFTWARE & SERVICES, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 56
GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR DATA MANAGEMENT SOFTWARE & SERVICES, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 57
IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 58
KEY IMMUNOASSAY ANALYZERS AVAILABLE WORLDWIDE
 
 
 
 
 
 
TABLE 59
IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 60
IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY REGION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 61
NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 62
EUROPE: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 63
ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 64
LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 65
GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 66
KEY ELISA ANALYZERS AVAILABLE WORLDWIDE
 
 
 
 
 
 
TABLE 67
IN VITRO DIAGNOSTICS MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAYS, BY REGION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 68
NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAYS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 69
EUROPE: IN VITRO DIAGNOSTICS MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAYS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 70
ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAYS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 71
LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAYS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 72
GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAYS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 73
KEY CHEMILUMINESCENCE IMMUNOASSAY SYSTEMS AVAILABLE WORLDWIDE
 
 
 
 
 
 
TABLE 74
IN VITRO DIAGNOSTICS MARKET FOR CHEMILUMINESCENCE IMMUNOASSAYS, BY REGION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 75
NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CHEMILUMINESCENCE IMMUNOASSAYS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 76
EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CHEMILUMINESCENCE IMMUNOASSAYS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 77
ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR CHEMILUMINESCENCE IMMUNOASSAYS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 78
LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CHEMILUMINESCENCE IMMUNOASSAYS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 79
GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR CHEMILUMINESCENCE IMMUNOASSAYS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 80
IN VITRO DIAGNOSTICS MARKET FOR IMMUNOFLUORESCENCE ASSAYS, BY REGION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 81
NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOFLUORESCENCE ASSAYS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 82
EUROPE: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOFLUORESCENCE ASSAYS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 83
ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOFLUORESCENCE ASSAYS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 84
LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOFLUORESCENCE ASSAYS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 85
GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOFLUORESCENCE ASSAYS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 86
KEY RAPID TESTS AVAILABLE WORLDWIDE
 
 
 
 
 
 
TABLE 87
IN VITRO DIAGNOSTICS MARKET FOR RAPID TESTS, BY REGION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 88
NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR RAPID TESTS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 89
EUROPE: IN VITRO DIAGNOSTICS MARKET FOR RAPID TESTS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 90
ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR RAPID TESTS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 91
LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR RAPID TESTS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 92
GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR RAPID TESTS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 93
IN VITRO DIAGNOSTICS MARKET FOR ENZYME-LINKED IMMUNOSPOT ASSAYS, BY REGION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 94
NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ENZYME-LINKED IMMUNOSPOT ASSAYS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 95
EUROPE: IN VITRO DIAGNOSTICS MARKET FOR ENZYME-LINKED IMMUNOSPOT ASSAYS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 96
ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR ENZYME-LINKED IMMUNOSPOT ASSAYS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 97
LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ENZYME-LINKED IMMUNOSPOT ASSAYS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 98
GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR ENZYME-LINKED IMMUNOSPOT ASSAYS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 99
KEY WESTERN BLOTTING SYSTEMS AVAILABLE WORLDWIDE
 
 
 
 
 
 
TABLE 100
IN VITRO DIAGNOSTICS MARKET FOR WESTERN BLOTTING, BY REGION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 101
NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR WESTERN BLOTTING, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 102
EUROPE: IN VITRO DIAGNOSTICS MARKET FOR WESTERN BLOTTING, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 103
ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR WESTERN BLOTTING, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 104
LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR WESTERN BLOTTING, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 105
GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR WESTERN BLOTTING, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 106
IN VITRO DIAGNOSTICS MARKET FOR OTHER IMMUNOASSAY TECHNOLOGIES, BY REGION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 107
NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER IMMUNOASSAY TECHNOLOGIES, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 108
EUROPE: IN VITRO DIAGNOSTICS MARKET FOR OTHER IMMUNOASSAY TECHNOLOGIES, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 109
ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR OTHER IMMUNOASSAY TECHNOLOGIES, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 110
LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER IMMUNOASSAY TECHNOLOGIES, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 111
GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR OTHER IMMUNOASSAY TECHNOLOGIES, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 112
CLINICAL CHEMISTRY ANALYZERS FOR HIGH AND MID-VOLUME LABORATORIES AVAILABLE WORLDWIDE
 
 
 
 
 
 
TABLE 113
CLINICAL CHEMISTRY ANALYZERS FOR LOW-VOLUME LABORATORIES AVAILABLE WORLDWIDE
 
 
 
 
 
 
TABLE 114
IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 115
IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY REGION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 116
NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 117
EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 118
ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 119
LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 120
GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 121
IN VITRO DIAGNOSTICS MARKET FOR BASIC METABOLIC PANELS, BY REGION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 122
NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BASIC METABOLIC PANELS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 123
EUROPE: IN VITRO DIAGNOSTICS MARKET FOR BASIC METABOLIC PANELS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 124
ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR BASIC METABOLIC PANELS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 125
LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BASIC METABOLIC PANELS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 126
GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR BASIC METABOLIC PANELS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 127
IN VITRO DIAGNOSTICS MARKET FOR LIVER PANELS, BY REGION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 128
NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR LIVER PANELS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 129
EUROPE: IN VITRO DIAGNOSTICS MARKET FOR LIVER PANELS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 130
ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR LIVER PANELS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 131
LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR LIVER PANELS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 132
GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR LIVER PANELS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 133
IN VITRO DIAGNOSTICS MARKET FOR RENAL PROFILES, BY REGION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 134
NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR RENAL PROFILES, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 135
EUROPE: IN VITRO DIAGNOSTICS MARKET FOR RENAL PROFILES, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 136
ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR RENAL PROFILES, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 137
LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR RENAL PROFILES, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 138
GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR RENAL PROFILES, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 139
IN VITRO DIAGNOSTICS MARKET FOR LIPID PROFILES, BY REGION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 140
NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR LIPID PROFILES, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 141
EUROPE: IN VITRO DIAGNOSTICS MARKET FOR LIPID PROFILES, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 142
ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR LIPID PROFILES, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 143
LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR LIPID PROFILES, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 144
GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR LIPID PROFILES, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 145
IN VITRO DIAGNOSTICS MARKET FOR THYROID FUNCTION PROFILES, BY REGION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 146
NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR THYROID FUNCTION PROFILES, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 147
EUROPE: IN VITRO DIAGNOSTICS MARKET FOR THYROID FUNCTION PROFILES, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 148
ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR THYROID FUNCTION PROFILES, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 149
LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR THYROID FUNCTION PROFILES, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 150
GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR THYROID FUNCTION PROFILES, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 151
REFERENCE RANGES AND ABNORMAL CONDITIONS FOR KEY ELECTROLYTES
 
 
 
 
 
 
TABLE 152
IN VITRO DIAGNOSTICS MARKET FOR ELECTROLYTE PANELS, BY REGION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 153
NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ELECTROLYTE PANELS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 154
EUROPE: IN VITRO DIAGNOSTICS MARKET FOR ELECTROLYTE PANELS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 155
ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR ELECTROLYTE PANELS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 156
LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ELECTROLYTE PANELS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 157
GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR ELECTROLYTE PANELS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 158
IN VITRO DIAGNOSTICS MARKET FOR SPECIALTY CHEMICAL TESTS, BY REGION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 159
NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR SPECIALTY CHEMICAL TESTS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 160
EUROPE: IN VITRO DIAGNOSTICS MARKET FOR SPECIALTY CHEMICAL TESTS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 161
ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR SPECIALTY CHEMICAL TESTS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 162
LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR SPECIALTY CHEMICAL TESTS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 163
GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR SPECIALTY CHEMICAL TESTS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 164
KEY AUTOMATED MOLECULAR DIAGNOSTIC PLATFORMS AVAILABLE WORLDWIDE
 
 
 
 
 
 
TABLE 165
IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 166
IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY REGION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 167
NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 168
EUROPE: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 169
ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 170
LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 171
GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 172
KEY POLYMERASE CHAIN REACTION INSTRUMENTS AVAILABLE WORLDWIDE
 
 
 
 
 
 
TABLE 173
IN VITRO DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 174
NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 175
EUROPE: IN VITRO DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 176
ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 177
LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 178
GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 179
KEY ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY INSTRUMENTS AVAILABLE WORLDWIDE
 
 
 
 
 
 
TABLE 180
IN VITRO DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY REGION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 181
NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 182
EUROPE: IN VITRO DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 183
ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 184
LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 185
GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 186
KEY NEXT-GENERATION SEQUENCING-BASED INSTRUMENTS AVAILABLE WORLDWIDE
 
 
 
 
 
 
TABLE 187
IN VITRO DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY REGION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 188
NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 189
EUROPE: IN VITRO DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 190
ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 191
LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 192
GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 193
IN VITRO DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY REGION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 194
NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 195
EUROPE: IN VITRO DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 196
ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 197
LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 198
GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 199
IN VITRO DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY REGION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 200
NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 201
EUROPE: IN VITRO DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 202
ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 203
LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 204
GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 205
IN VITRO DIAGNOSTICS MARKET FOR OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES, BY REGION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 206
NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 207
EUROPE: IN VITRO DIAGNOSTICS MARKET FOR OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 208
ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 209
LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 210
GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 211
DIABETES-RELATED HEALTH EXPENDITURE PER PERSON, 2021 VS. 2030 VS. 2045 (USD)
 
 
 
 
 
 
TABLE 212
IN VITRO DIAGNOSTICS MARKET FOR GLUCOSE MONITORING, BY REGION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 213
NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR GLUCOSE MONITORING, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 214
EUROPE: IN VITRO DIAGNOSTICS MARKET FOR GLUCOSE MONITORING, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 215
ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR GLUCOSE MONITORING, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 216
LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR GLUCOSE MONITORING, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 217
GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR GLUCOSE MONITORING, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 218
IN VITRO DIAGNOSTICS MARKET FOR HEMATOLOGY, BY REGION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 219
NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 220
EUROPE: IN VITRO DIAGNOSTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 221
ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 222
LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 223
GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 224
IN VITRO DIAGNOSTICS MARKET FOR MICROBIOLOGY, BY REGION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 225
NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR MICROBIOLOGY, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 226
EUROPE: IN VITRO DIAGNOSTICS MARKET FOR MICROBIOLOGY, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 227
ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR MICROBIOLOGY, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 228
LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR MICROBIOLOGY, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 229
GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR MICROBIOLOGY, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 230
IN VITRO DIAGNOSTICS MARKET FOR COAGULATION & HEMOSTASIS, BY REGION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 231
NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION & HEMOSTASIS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 232
EUROPE: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION & HEMOSTASIS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 233
ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION & HEMOSTASIS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 234
LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION & HEMOSTASIS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 235
GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION & HEMOSTASIS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 236
KEY BLOOD GAS ANALYZERS AVAILABLE WORLDWIDE
 
 
 
 
 
 
TABLE 237
IN VITRO DIAGNOSTICS MARKET FOR BLOOD GAS ANALYZERS, BY REGION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 238
NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD GAS ANALYZERS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 239
EUROPE: IN VITRO DIAGNOSTICS MARKET FOR BLOOD GAS ANALYZERS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 240
ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR BLOOD GAS ANALYZERS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 241
LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD GAS ANALYZERS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 242
GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR BLOOD GAS ANALYZER, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 243
IN VITRO DIAGNOSTICS MARKET FOR URINALYSIS, BY REGION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 244
NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR URINALYSIS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 245
EUROPE: IN VITRO DIAGNOSTICS MARKET FOR URINALYSIS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 246
ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR URINALYSIS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 247
LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR URINALYSIS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 248
GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR URINALYSIS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 249
IN VITRO DIAGNOSTICS MARKET FOR CHROMATOGRAPHY & MASS SPECTROMETRY, BY REGION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 250
NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CHROMATOGRAPHY & MASS SPECTROMETRY, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 251
EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CHROMATOGRAPHY & MASS SPECTROMETRY, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 252
ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR CHROMATOGRAPHY & MASS SPECTROMETRY, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 253
LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CHROMATOGRAPHY & MASS SPECTROMETRY, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 254
GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR CHROMATOGRAPHY & MASS SPECTROMETRY, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 255
IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 256
KEY BLOOD, SERUM, AND PLASMA SAMPLE TYPE-BASED PRODUCTS AVAILABLE WORLDWIDE
 
 
 
 
 
 
TABLE 257
IN VITRO DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SPECIMENS, BY REGION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 258
NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SPECIMENS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 259
EUROPE: IN VITRO DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SPECIMENS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 260
ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SPECIMENS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 261
LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SPECIMENS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 262
GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SPECIMENS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 263
IN VITRO DIAGNOSTICS MARKET FOR SALIVA SPECIMENS, BY REGION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 264
NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR SALIVA SPECIMENS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 265
EUROPE: IN VITRO DIAGNOSTICS MARKET FOR SALIVA SPECIMENS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 266
ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR SALIVA SPECIMENS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 267
LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR SALIVA SPECIMENS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 268
GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR SALIVA SPECIMENS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 269
KEY URINE SAMPLE TYPE-BASED PRODUCTS AVAILABLE WORLDWIDE
 
 
 
 
 
 
TABLE 270
IN VITRO DIAGNOSTICS MARKET FOR URINE SPECIMENS, BY REGION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 271
NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR URINE SPECIMENS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 272
EUROPE: IN VITRO DIAGNOSTICS MARKET FOR URINE SPECIMENS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 273
ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR URINE SPECIMENS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 274
LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR URINE SPECIMENS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 275
GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR URINE SPECIMENS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 276
IN VITRO DIAGNOSTICS MARKET FOR OTHER SPECIMENS, BY REGION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 277
NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 278
EUROPE: IN VITRO DIAGNOSTICS MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 279
ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 280
LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 281
GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 282
IN VITRO DIAGNOSTICS MARKET, BY SITE OF TESTING, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 283
IN VITRO DIAGNOSTICS MARKET FOR LABORATORY TESTS, BY TECHNOLOGY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 284
IN VITRO DIAGNOSTICS MARKET FOR LABORATORY TESTS, BY REGION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 285
NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR LABORATORY TESTS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 286
EUROPE: IN VITRO DIAGNOSTICS MARKET FOR LABORATORY TESTS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 287
ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR LABORATORY TESTS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 288
LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR LABORATORY TESTS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 289
GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR LABORATORY TESTS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 290
IN VITRO DIAGNOSTICS MARKET FOR POINT-OF-CARE TESTS, BY TECHNOLOGY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 291
IN VITRO DIAGNOSTICS MARKET FOR POINT-OF-CARE TESTS, BY REGION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 292
NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR POINT-OF-CARE TESTS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 293
EUROPE: IN VITRO DIAGNOSTICS MARKET FOR POINT-OF-CARE TESTS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 294
ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR POINT-OF-CARE TESTS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 295
LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR POINT-OF-CARE TESTS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 296
GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR POINT-OF-CARE TESTS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 297
IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 298
IN VITRO DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 299
NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 300
EUROPE: IN VITRO DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 301
ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 302
LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 303
GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 304
INCREASING INCIDENCE OF CANCER, BY REGION, 2022 VS. 2040
 
 
 
 
 
 
TABLE 305
LIST OF APPROVED COMPANION DIAGNOSTIC DEVICES, 2022–2024
 
 
 
 
 
 
TABLE 306
IN VITRO DIAGNOSTICS MARKET FOR ONCOLOGY, BY REGION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 307
NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ONCOLOGY, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 308
EUROPE: IN VITRO DIAGNOSTICS MARKET FOR ONCOLOGY, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 309
ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR ONCOLOGY, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 310
LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ONCOLOGY, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 311
GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR ONCOLOGY, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 312
IN VITRO DIAGNOSTICS MARKET FOR ENDOCRINOLOGY, BY REGION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 313
NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 314
EUROPE: IN VITRO DIAGNOSTICS MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 315
ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 316
LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 317
GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 318
IN VITRO DIAGNOSTICS MARKET FOR CARDIOLOGY, BY REGION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 319
NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CARDIOLOGY, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 320
EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CARDIOLOGY, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 321
ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR CARDIOLOGY, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 322
LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CARDIOLOGY, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 323
GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR CARDIOLOGY, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 324
IN VITRO DIAGNOSTICS MARKET FOR BLOOD SCREENING, BY REGION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 325
NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD SCREENING, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 326
EUROPE: IN VITRO DIAGNOSTICS MARKET FOR BLOOD SCREENING, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 327
ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR BLOOD SCREENING, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 328
LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD SCREENING, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 329
GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR BLOOD SCREENING, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 330
IN VITRO DIAGNOSTICS MARKET FOR GENETIC TESTING, BY REGION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 331
NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR GENETIC TESTING, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 332
EUROPE: IN VITRO DIAGNOSTICS MARKET FOR GENETIC TESTING, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 333
ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR GENETIC TESTING, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 334
LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR GENETIC TESTING, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 335
GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR GENETIC TESTING, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 336
IN VITRO DIAGNOSTICS MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 337
NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 338
EUROPE: IN VITRO DIAGNOSTICS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 339
ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 340
LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 341
GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 342
IN VITRO DIAGNOSTICS MARKET FOR ALLERGY DIAGNOSTICS, BY REGION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 343
NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ALLERGY DIAGNOSTICS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 344
EUROPE: IN VITRO DIAGNOSTICS MARKET FOR ALLERGY DIAGNOSTICS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 345
ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR ALLERGY DIAGNOSTICS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 346
LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ALLERGY DIAGNOSTICS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 347
GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR ALLERGY DIAGNOSTICS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 348
KEY PRODUCTS FOR DRUG MONITORING WORLDWIDE
 
 
 
 
 
 
TABLE 349
KEY IVD PRODUCTS FOR DRUG TESTING WORLDWIDE
 
 
 
 
 
 
TABLE 350
IN VITRO DIAGNOSTICS MARKET FOR DRUG MONITORING & TESTING, BY REGION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 351
NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 352
EUROPE: IN VITRO DIAGNOSTICS MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 353
ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 354
LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 355
GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 356
KEY PRODUCTS FOR BONE & MINERAL DISORDERS WORLDWIDE
 
 
 
 
 
 
TABLE 357
IN VITRO DIAGNOSTICS MARKET FOR BONE & MINERAL DISORDERS, BY REGION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 358
NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BONE & MINERAL DISORDERS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 359
EUROPE: IN VITRO DIAGNOSTICS MARKET FOR BONE & MINERAL DISORDERS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 360
ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR BONE & MINERAL DISORDERS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 361
LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BONE & MINERAL DISORDERS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 362
GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR BONE & MINERAL DISORDERS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 363
IN VITRO DIAGNOSTICS MARKET FOR COAGULATION TESTING, BY REGION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 364
NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION TESTING, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 365
EUROPE: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION TESTING, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 366
ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION TESTING, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 367
LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION TESTING, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 368
GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION TESTING, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 369
IN VITRO DIAGNOSTICS MARKET FOR BLOOD GROUP TYPING, BY REGION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 370
NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD GROUP TYPING, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 371
EUROPE: IN VITRO DIAGNOSTICS MARKET FOR BLOOD GROUP TYPING, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 372
ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR BLOOD GROUP TYPING, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 373
LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD GROUP TYPING, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 374
GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR BLOOD GROUP TYPING, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 375
IN VITRO DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 376
NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 377
EUROPE: IN VITRO DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 378
ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 379
LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 380
GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 381
IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 382
IN VITRO DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY REGION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 383
NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 384
EUROPE: IN VITRO DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 385
ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 386
LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 387
GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 388
IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 389
IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY REGION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 390
NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 391
EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 392
ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 393
LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 394
GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 395
IN VITRO DIAGNOSTICS MARKET FOR LARGE REFERENCE LABORATORIES, BY REGION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 396
NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR LARGE REFERENCE LABORATORIES, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 397
EUROPE: IN VITRO DIAGNOSTICS MARKET FOR LARGE REFERENCE LABORATORIES, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 398
ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR LARGE REFERENCE LABORATORIES, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 399
LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR LARGE REFERENCE LABORATORIES, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 400
GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR LARGE REFERENCE LABORATORIES, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 401
IN VITRO DIAGNOSTICS MARKET FOR SMALL AND MEDIUM-SIZED LABORATORIES, BY REGION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 402
NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR SMALL AND MEDIUM-SIZED LABORATORIES, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 403
EUROPE: IN VITRO DIAGNOSTICS MARKET FOR SMALL AND MEDIUM-SIZED LABORATORIES, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 404
ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR SMALL AND MEDIUM-SIZED LABORATORIES, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 405
LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR SMALL AND MEDIUM-SIZED LABORATORIES, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 406
GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR SMALL AND MEDIUM-SIZED LABORATORIES, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 407
IN VITRO DIAGNOSTICS MARKET FOR BLOOD BANKS, BY REGION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 408
NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD BANKS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 409
EUROPE: IN VITRO DIAGNOSTICS MARKET FOR BLOOD BANKS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 410
ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR BLOOD BANKS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 411
LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD BANKS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 412
GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR BLOOD BANKS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 413
IN VITRO DIAGNOSTICS MARKET FOR HOME CARE SETTINGS, BY REGION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 414
NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 415
EUROPE: IN VITRO DIAGNOSTICS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 416
ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 417
LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 418
GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 419
IN VITRO DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 420
NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 421
EUROPE: IN VITRO DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 422
ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 423
LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 424
GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 425
IN VITRO DIAGNOSTICS MARKET FOR ACADEMIC INSTITUTES, BY REGION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 426
NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 427
EUROPE: IN VITRO DIAGNOSTICS MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 428
ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 429
LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 430
GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 431
IN VITRO DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 432
NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 433
EUROPE: IN VITRO DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 434
ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 435
LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 436
GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 437
IN VITRO DIAGNOSTICS MARKET, BY REGION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 438
NORTH AMERICA: KEY MACROECONOMIC INDICATORS
 
 
 
 
 
 
TABLE 439
NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 440
NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 441
NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 442
NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 443
NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 444
NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 445
NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 446
NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 447
NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 448
NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 449
NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 450
US: KEY MACROECONOMIC INDICATORS
 
 
 
 
 
 
TABLE 451
US: NUMBER OF IN VITRO DIAGNOSTICS TESTS CONDUCTED, 2022–2030 (BILLION)
 
 
 
 
 
 
TABLE 452
US: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 453
US: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 454
US: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 455
US: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 456
US: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 457
US: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 458
US: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 459
US: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 460
US: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 461
US: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 462
CANADA: ESTIMATED PREVALENCE OF DIABETES, 2024 VS. 2034
 
 
 
 
 
 
TABLE 463
CANADA: KEY MACROECONOMIC INDICATORS
 
 
 
 
 
 
TABLE 464
CANADA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 465
CANADA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 466
CANADA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 467
CANADA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 468
CANADA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 469
CANADA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 470
CANADA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 471
CANADA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 472
CANADA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 473
CANADA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 474
EUROPE: KEY MACROECONOMIC INDICATORS
 
 
 
 
 
 
TABLE 475
EUROPE: IN VITRO DIAGNOSTICS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 476
EUROPE: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 477
EUROPE: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 478
EUROPE: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 479
EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 480
EUROPE: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 481
EUROPE: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 482
EUROPE: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 483
EUROPE: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 484
EUROPE: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 485
EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 486
GERMANY: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 487
GERMANY: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 488
GERMANY: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 489
GERMANY: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 490
GERMANY: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 491
GERMANY: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 492
GERMANY: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 493
GERMANY: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 494
GERMANY: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 495
GERMANY: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 496
FRANCE: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 497
FRANCE: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 498
FRANCE: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 499
FRANCE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 500
FRANCE: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 501
FRANCE: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 502
FRANCE: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 503
FRANCE: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 504
FRANCE: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 505
FRANCE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 506
UK: KEY MACROECONOMIC INDICATORS
 
 
 
 
 
 
TABLE 507
UK: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 508
UK: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 509
UK: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 510
UK: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 511
UK: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 512
UK: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 513
UK: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 514
UK: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 515
UK: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 516
UK: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 517
ITALY: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 518
ITALY: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 519
ITALY: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 520
ITALY: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 521
ITALY: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 522
ITALY: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 523
ITALY: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 524
ITALY: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 525
ITALY: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 526
ITALY: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 527
SPAIN: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 528
SPAIN: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 529
SPAIN: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 530
SPAIN: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 531
SPAIN: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 532
SPAIN: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 533
SPAIN: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 534
SPAIN: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 535
SPAIN: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 536
SPAIN: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 537
RUSSIA: KEY MACROECONOMIC INDICATORS
 
 
 
 
 
 
TABLE 538
RUSSIA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 539
RUSSIA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 540
RUSSIA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 541
RUSSIA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 542
RUSSIA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 543
RUSSIA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 544
RUSSIA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 545
RUSSIA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 546
RUSSIA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 547
RUSSIA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 548
SWITZERLAND: KEY MACROECONOMIC INDICATORS
 
 
 
 
 
 
TABLE 549
SWITZERLAND: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 550
SWITZERLAND: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 551
SWITZERLAND: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 552
SWITZERLAND: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 553
SWITZERLAND: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 554
SWITZERLAND: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 555
SWITZERLAND: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 556
SWITZERLAND: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 557
SWITZERLAND: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 558
SWITZERLAND: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 559
REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 560
REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 561
REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 562
REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 563
REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 564
REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 565
REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 566
REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 567
REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 568
REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 569
ASIA PACIFIC: KEY MACROECONOMIC INDICATORS
 
 
 
 
 
 
TABLE 570
ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 571
ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 572
ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 573
ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 574
ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 575
ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 576
ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 577
ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 578
ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 579
ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 580
ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 581
JAPAN: KEY MACROECONOMIC INDICATORS
 
 
 
 
 
 
TABLE 582
JAPAN: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 583
JAPAN: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 584
JAPAN: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 585
JAPAN: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 586
JAPAN: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 587
JAPAN: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 588
JAPAN: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 589
JAPAN: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 590
JAPAN: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 591
JAPAN: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 592
CHINA: KEY MACROECONOMIC INDICATORS
 
 
 
 
 
 
TABLE 593
CHINA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 594
CHINA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 595
CHINA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 596
CHINA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 597
CHINA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 598
CHINA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 599
CHINA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 600
CHINA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 601
CHINA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 602
CHINA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 603
INDIA: KEY MACROECONOMIC INDICATORS
 
 
 
 
 
 
TABLE 604
INDIA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 605
INDIA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 606
INDIA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 607
INDIA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 608
INDIA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 609
INDIA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 610
INDIA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 611
INDIA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 612
INDIA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 613
INDIA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 614
SOUTH KOREA: KEY MACROECONOMIC INDICATORS
 
 
 
 
 
 
TABLE 615
SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 616
SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 617
SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 618
SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 619
SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 620
SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 621
SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 622
SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 623
SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 624
SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 625
AUSTRALIA: KEY MACROECONOMIC INDICATORS
 
 
 
 
 
 
TABLE 626
AUSTRALIA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 627
AUSTRALIA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 628
AUSTRALIA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 629
AUSTRALIA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 630
AUSTRALIA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 631
AUSTRALIA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 632
AUSTRALIA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 633
AUSTRALIA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 634
AUSTRALIA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 635
AUSTRALIA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 636
SINGAPORE: KEY MACROECONOMIC INDICATORS
 
 
 
 
 
 
TABLE 637
SINGAPORE: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 638
SINGAPORE: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 639
SINGAPORE: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 640
SINGAPORE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 641
SINGAPORE: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 642
SINGAPORE: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 643
SINGAPORE: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 644
SINGAPORE: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 645
SINGAPORE: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 646
SINGAPORE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 647
REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 648
REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 649
REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 650
REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 651
REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 652
REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 653
REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 654
REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 655
REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 656
REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 657
LATIN AMERICA: KEY MACROECONOMIC INDICATORS
 
 
 
 
 
 
TABLE 658
LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 659
LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 660
LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 661
LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 662
LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 663
LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 664
LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 665
LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 666
LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 667
LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 668
LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 669
BRAZIL: KEY MACROECONOMIC INDICATORS
 
 
 
 
 
 
TABLE 670
BRAZIL: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 671
BRAZIL: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 672
BRAZIL: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 673
BRAZIL: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 674
BRAZIL: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 675
BRAZIL: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 676
BRAZIL: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 677
BRAZIL: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 678
BRAZIL: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 679
BRAZIL: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 680
MEXICO: KEY MACROECONOMIC INDICATORS
 
 
 
 
 
 
TABLE 681
MEXICO: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 682
MEXICO: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 683
MEXICO: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 684
MEXICO: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 685
MEXICO: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 686
MEXICO: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 687
MEXICO: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 688
MEXICO: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 689
MEXICO: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 690
MEXICO: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 691
REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 692
REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 693
REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 694
REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 695
REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 696
REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 697
REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 698
REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 699
REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 700
REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 701
MIDDLE EAST & AFRICA: KEY MACROECONOMIC INDICATORS
 
 
 
 
 
 
TABLE 702
MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 703
MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 704
MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 705
MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 706
MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 707
MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 708
MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 709
MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 710
MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 711
MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 712
GCC COUNTRIES: KEY MACROECONOMIC INDICATORS
 
 
 
 
 
 
TABLE 713
GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 714
GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 715
GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 716
GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 717
GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 718
GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 719
GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 720
GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 721
GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 722
GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 723
GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 724
SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 725
SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 726
SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 727
SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 728
SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 729
SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 730
SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 731
SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 732
SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 733
SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 734
UAE: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 735
UAE: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 736
UAE: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 737
UAE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 738
UAE: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 739
UAE: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 740
UAE: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 741
UAE: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 742
UAE: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 743
UAE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 744
OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 745
OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 746
OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 747
OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 748
OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 749
OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 750
OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 751
OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 752
OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 753
OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 754
OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS, JANUARY 2022–APRIL 2025
 
 
 
 
 
 
TABLE 755
IN VITRO DIAGNOSTICS MARKET: DEGREE OF COMPETITION
 
 
 
 
 
 
TABLE 756
IN VITRO DIAGNOSTICS MARKET: REGION FOOTPRINT
 
 
 
 
 
 
TABLE 757
IN VITRO DIAGNOSTICS MARKET: PRODUCT & SERVICE FOOTPRINT
 
 
 
 
 
 
TABLE 758
IN VITRO DIAGNOSTICS MARKET: TECHNOLOGY FOOTPRINT
 
 
 
 
 
 
TABLE 759
IN VITRO DIAGNOSTICS MARKET: END-USER FOOTPRINT
 
 
 
 
 
 
TABLE 760
IN VITRO DIAGNOSTICS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
 
 
 
 
 
 
TABLE 761
IN VITRO DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES
 
 
 
 
 
 
TABLE 762
IN VITRO DIAGNOSTICS MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–APRIL 2025
 
 
 
 
 
 
TABLE 763
IN VITRO DIAGNOSTICS MARKET: DEALS, JANUARY 2022–APRIL 2025
 
 
 
 
 
 
TABLE 764
IN VITRO DIAGNOSTICS MARKET: EXPANSIONS, JANUARY 2022–APRIL 2025
 
 
 
 
 
 
TABLE 765
IN VITRO DIAGNOSTICS MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025
 
 
 
 
 
 
TABLE 766
IN VITRO DIAGNOSTICS MARKET: DEALS, JANUARY 2022–MARCH 2025
 
 
 
 
 
 
TABLE 767
AI-DRIVEN PRODUCTS & SERVICES PROVIDED BY KEY PLAYERS
 
 
 
 
 
 
TABLE 768
DANAHER: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 769
DANAHER: PRODUCTS/SERVICES OFFERED
 
 
 
 
 
 
TABLE 770
DANAHER: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025
 
 
 
 
 
 
TABLE 771
DANAHER: DEALS, JANUARY 2022–MARCH 2025
 
 
 
 
 
 
TABLE 772
DANAHER: EXPANSIONS, JANUARY 2022–MARCH 2024
 
 
 
 
 
 
TABLE 773
F. HOFFMANN-LA ROCHE LTD: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 774
F. HOFFMANN-LA ROCHE LTD: CURRENCY CONVERSION, 2022–2024
 
 
 
 
 
 
TABLE 775
F. HOFFMANN-LA ROCHE LTD: PRODUCTS/SERVICES OFFERED
 
 
 
 
 
 
TABLE 776
F. HOFFMANN-LA ROCHE LTD: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025
 
 
 
 
 
 
TABLE 777
F. HOFFMANN-LA ROCHE LTD: DEALS, JANUARY 2022–MARCH 2025
 
 
 
 
 
 
TABLE 778
F. HOFFMANN-LA ROCHE LTD: EXPANSIONS, JANUARY 2022–MARCH 2024
 
 
 
 
 
 
TABLE 779
ABBOTT: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 780
ABBOTT: PRODUCTS/SERVICES OFFERED
 
 
 
 
 
 
TABLE 781
ABBOTT: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025
 
 
 
 
 
 
TABLE 782
ABBOTT: DEALS, JANUARY 2022–MARCH 2025
 
 
 
 
 
 
TABLE 783
ABBOTT: EXPANSIONS, JANUARY 2022–MARCH 2025
 
 
 
 
 
 
TABLE 784
SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 785
SIEMENS HEALTHINEERS AG: CURRENCY CONVERSION, 2022–2024
 
 
 
 
 
 
TABLE 786
SIEMENS HEALTHINEERS AG: PRODUCTS/SERVICES OFFERED
 
 
 
 
 
 
TABLE 787
SIEMENS HEALTHINEERS AG: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025
 
 
 
 
 
 
TABLE 788
SIEMENS HEALTHINEERS AG: DEALS, JANUARY 2022–MARCH 2025
 
 
 
 
 
 
TABLE 789
SIEMENS HEALTHINEERS AG: EXPANSIONS, JANUARY 2022–MARCH 2025
 
 
 
 
 
 
TABLE 790
THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 791
THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES OFFERED
 
 
 
 
 
 
TABLE 792
THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025
 
 
 
 
 
 
TABLE 793
THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2022–MARCH 2025
 
 
 
 
 
 
TABLE 794
THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2022–MARCH 2025
 
 
 
 
 
 
TABLE 795
ILLUMINA, INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 796
ILLUMINA, INC.: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 797
ILLUMINA, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025
 
 
 
 
 
 
TABLE 798
ILLUMINA, INC.: DEALS, JANUARY 2022–MARCH 2025
 
 
 
 
 
 
TABLE 799
ILLUMINA, INC.: EXPANSIONS, JANUARY 2022–MARCH 2025
 
 
 
 
 
 
TABLE 800
ILLUMINA, INC.: OTHER DEVELOPMENTS, JANUARY 2022–MARCH 2025
 
 
 
 
 
 
TABLE 801
HOLOGIC, INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 802
HOLOGIC, INC.: PRODUCTS/SERVICES OFFERED
 
 
 
 
 
 
TABLE 803
HOLOGIC, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025
 
 
 
 
 
 
TABLE 804
HOLOGIC, INC.: DEALS, JANUARY 2022–MARCH 2025
 
 
 
 
 
 
TABLE 805
HOLOGIC, INC.: EXPANSIONS, JANUARY 2022–MARCH 2025
 
 
 
 
 
 
TABLE 806
BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 807
BIO-RAD LABORATORIES, INC.: PRODUCTS/SERVICES OFFERED
 
 
 
 
 
 
TABLE 808
BIO-RAD LABORATORIES, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025
 
 
 
 
 
 
TABLE 809
BIO-RAD LABORATORIES, INC.: DEALS, JANUARY 2022–MARCH 2025
 
 
 
 
 
 
TABLE 810
BIOMÉRIEUX: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 811
BIOMÉRIEUX: CURRENCY CONVERSION, 2022–2024
 
 
 
 
 
 
TABLE 812
BIOMÉRIEUX: PRODUCTS/SERVICES OFFERED
 
 
 
 
 
 
TABLE 813
BIOMÉRIEUX: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025
 
 
 
 
 
 
TABLE 814
BIOMÉRIEUX: DEALS, JANUARY 2022–MARCH 2025
 
 
 
 
 
 
TABLE 815
BIOMÉRIEUX: EXPANSIONS, JANUARY 2022–MARCH 2025
 
 
 
 
 
 
TABLE 816
SYSMEX CORPORATION: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 817
SYSMEX CORPORATION: CURRENCY CONVERSION, 2022–2024
 
 
 
 
 
 
TABLE 818
SYSMEX CORPORATION: PRODUCTS/SERVICES OFFERED
 
 
 
 
 
 
TABLE 819
SYSMEX CORPORATION: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025
 
 
 
 
 
 
TABLE 820
SYSMEX CORPORATION: DEALS, JANUARY 2022–MARCH 2025
 
 
 
 
 
 
TABLE 821
SYSMEX CORPORATION: EXPANSIONS, JANUARY 2022–MARCH 2025
 
 
 
 
 
 
TABLE 822
REVVITY: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 823
REVVITY: PRODUCTS/SERVICES OFFERED
 
 
 
 
 
 
TABLE 824
REVVITY: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025
 
 
 
 
 
 
TABLE 825
REVVITY: DEALS, JANUARY 2022–MARCH 2025
 
 
 
 
 
 
TABLE 826
REVVITY: OTHER DEVELOPMENTS, JANUARY 2022–MARCH 2025
 
 
 
 
 
 
TABLE 827
BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 828
BECTON, DICKINSON AND COMPANY: PRODUCTS/SERVICES OFFERED
 
 
 
 
 
 
TABLE 829
BECTON, DICKINSON AND COMPANY: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025
 
 
 
 
 
 
TABLE 830
BECTON, DICKINSON AND COMPANY: DEALS, JANUARY 2022–MARCH 2025
 
 
 
 
 
 
TABLE 831
BECTON, DICKINSON AND COMPANY: EXPANSIONS, JANUARY 2022–MARCH 2025
 
 
 
 
 
 
TABLE 832
AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 833
AGILENT TECHNOLOGIES, INC: PRODUCTS/SERVICES OFFERED
 
 
 
 
 
 
TABLE 834
AGILENT TECHNOLOGIES, INC: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025
 
 
 
 
 
 
TABLE 835
AGILENT TECHNOLOGIES, INC: DEALS, JANUARY 2022–MARCH 2025
 
 
 
 
 
 
TABLE 836
AGILENT TECHNOLOGIES, INC: OTHER DEVELOPMENTS, JANUARY 2022–MARCH 2025
 
 
 
 
 
 
TABLE 837
QIAGEN: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 838
QIAGEN: PRODUCTS/SERVICES OFFERED
 
 
 
 
 
 
TABLE 839
QIAGEN: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025
 
 
 
 
 
 
TABLE 840
QIAGEN: DEALS, JANUARY 2022–MARCH 2025
 
 
 
 
 
 
TABLE 841
DIASORIN S.P.A.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 842
DIASORIN S.P.A.: CURRENCY CONVERSION, 2021-2023
 
 
 
 
 
 
TABLE 843
DIASORIN S.P.A.: PRODUCTS/SERVICES OFFERED
 
 
 
 
 
 
TABLE 844
DIASORIN S.P.A.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025
 
 
 
 
 
 
TABLE 845
DIASORIN S.P.A.: DEALS, JANUARY 2022–MARCH 2025
 
 
 
 
 
 
TABLE 846
GRIFOLS, S.A.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 847
GRIFOLS, S.A.: CURRENCY CONVERSION, 2022–2024
 
 
 
 
 
 
TABLE 848
GRIFOLS, S.A.: PRODUCTS/SERVICES OFFERED
 
 
 
 
 
 
TABLE 849
GRIFOLS, S.A.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025
 
 
 
 
 
 
TABLE 850
GRIFOLS, S.A.: DEALS, JANUARY 2022–MARCH 2025
 
 
 
 
 
 
TABLE 851
WERFEN: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 852
WERFEN: PRODUCTS/SERVICES OFFERED
 
 
 
 
 
 
TABLE 853
WERFEN: DEALS, JANUARY 2022–MARCH 2025
 
 
 
 
 
 
TABLE 854
WERFEN: EXPANSIONS, JANUARY 2022–MARCH 2025
 
 
 
 
 
 
TABLE 855
QUIDELORTHO CORPORATION: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 856
QUIDELORTHO CORPORATION: PRODUCTS/SERVICES OFFERED
 
 
 
 
 
 
TABLE 857
QUIDELORTHO CORPORATION: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025
 
 
 
 
 
 
TABLE 858
QUIDELORTHO CORPORATION: DEALS, JANUARY 2022–MARCH 2025
 
 
 
 
 
 
TABLE 859
QUIDELORTHO CORPORATION: EXPANSIONS, JANUARY 2022–MARCH 2024
 
 
 
 
 
 
TABLE 860
DEVYSER: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 861
BIOSYNEX SA: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 862
SURMODICS, INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 863
MENARINI SILICON BIOSYSTEMS: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 864
SPEEDX PTY. LTD.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 865
GENSPEED BIOTECH GMBH: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 866
MERCK KGAA: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 867
CARIS LIFE SCIENCES: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 868
ARKRAY, INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 869
ACCELERATE DIAGNOSTICS, INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 870
CELLABS: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 871
J. MITRA & CO. PVT. LTD.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 872
EPITOPE DIAGNOSTICS, INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 873
BOSTER BIOLOGICAL TECHNOLOGY: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 874
ENZO BIOCHEM INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 875
GENETIC SIGNATURES: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 876
SAVYON DIAGNOSTICS: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 877
TRIVITRON HEALTHCARE: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 878
MDXHEALTH: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 879
CREATIVE DIAGNOSTICS: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 880
INBIOS INTERNATIONAL, INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 881
MACCURA BIOTECHNOLOGY CO., LTD.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 882
LUYE LIFE SCIENCES GROUP: COMPANY OVERVIEW
 
 
 
 
 
 
LIST OF FIGURES
 
 
 
 
 
 
 
FIGURE 1
IN VITRO DIAGNOSTICS MARKET SEGMENTATION AND REGIONAL SCOPE
 
 
 
 
 
 
FIGURE 2
RESEARCH DESIGN
 
 
 
 
 
 
FIGURE 3
BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
 
 
 
 
 
 
FIGURE 4
BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
 
 
 
 
 
 
FIGURE 5
GLOBAL IN VITRO DIAGNOSTICS MARKET: REVENUE SHARE ANALYSIS
 
 
 
 
 
 
FIGURE 6
CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
 
 
 
 
 
 
FIGURE 7
TOP-DOWN APPROACH
 
 
 
 
 
 
FIGURE 8
DATA TRIANGULATION METHODOLOGY
 
 
 
 
 
 
FIGURE 9
IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2025 VS. 2030 (USD MILLION)
 
 
 
 
 
 
FIGURE 10
IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2025 VS. 2030 (USD MILLION)
 
 
 
 
 
 
FIGURE 11
IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2025 VS. 2030 (USD MILLION)
 
 
 
 
 
 
FIGURE 12
IN VITRO DIAGNOSTICS MARKET, BY SITE OF TESTING, 2025 VS. 2030 (USD MILLION)
 
 
 
 
 
 
FIGURE 13
IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION)
 
 
 
 
 
 
FIGURE 14
IN VITRO DIAGNOSTICS MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
 
 
 
 
 
 
FIGURE 15
GEOGRAPHIC SNAPSHOT OF IN VITRO DIAGNOSTICS MARKET
 
 
 
 
 
 
FIGURE 16
GROWING PREVALENCE OF INFECTIOUS DISEASES AND RISING EMPHASIS ON NEED FOR EARLY DIAGNOSIS TO DRIVE MARKET
 
 
 
 
 
 
FIGURE 17
REAGENTS & KITS SEGMENT AND US LED NORTH AMERICAN IN VITRO DIAGNOSTICS MARKET IN 2024
 
 
 
 
 
 
FIGURE 18
CHINA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD
 
 
 
 
 
 
FIGURE 19
ASIA PACIFIC TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD
 
 
 
 
 
 
FIGURE 20
EMERGING ECONOMIES TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD
 
 
 
 
 
 
FIGURE 21
IN VITRO DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
 
 
 
 
 
 
FIGURE 22
IN VITRO DIAGNOSTIC REGULATION: CRITICAL AREAS OF IMPACT
 
 
 
 
 
 
FIGURE 23
TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
 
 
 
 
 
 
FIGURE 24
IN VITRO DIAGNOSTICS MARKET: VALUE CHAIN ANALYSIS
 
 
 
 
 
 
FIGURE 25
IN VITRO DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS
 
 
 
 
 
 
FIGURE 26
IN VITRO DIAGNOSTICS MARKET: ECOSYSTEM MAPPING
 
 
 
 
 
 
FIGURE 27
IN VITRO DIAGNOSTICS MARKET: INVESTMENT AND FUNDING SCENARIO, 2020−2023
 
 
 
 
 
 
FIGURE 28
IN VITRO DIAGNOSTICS MARKET: PATENT ANALYSIS, 2014–2024
 
 
 
 
 
 
FIGURE 29
US: REGULATORY PROCESS FOR IVD DEVICES
 
 
 
 
 
 
FIGURE 30
CANADA: REGULATORY PROCESS FOR IVD DEVICES IN CANADA
 
 
 
 
 
 
FIGURE 31
EUROPE: IN VITRO DIAGNOSTIC REGULATION (IVDR) TIMELINE
 
 
 
 
 
 
FIGURE 32
REGULATORY PROCESS FOR IVD DEVICES IN JAPAN
 
 
 
 
 
 
FIGURE 33
INDIA: REGULATORY PROCESS FOR IVD DEVICES
 
 
 
 
 
 
FIGURE 34
MEXICO: REGULATORY PROCESS FOR IVD DEVICES
 
 
 
 
 
 
FIGURE 35
IN VITRO DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS
 
 
 
 
 
 
FIGURE 36
INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF IVD PRODUCTS, BY PRODUCT & SERVICE
 
 
 
 
 
 
FIGURE 37
KEY BUYING CRITERIA, BY PRODUCT & SERVICE
 
 
 
 
 
 
FIGURE 38
AI USE CASES
 
 
 
 
 
 
FIGURE 39
NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET SNAPSHOT
 
 
 
 
 
 
FIGURE 40
ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET SNAPSHOT
 
 
 
 
 
 
FIGURE 41
IN VITRO DIAGNOSTICS MARKET: REVENUE ANALYSIS OF KEY PLAYERS, 2022–2024 (USD BILLION)
 
 
 
 
 
 
FIGURE 42
IN VITRO DIAGNOSTICS MARKET SHARE ANALYSIS, 2024
 
 
 
 
 
 
FIGURE 43
RANKING OF KEY PLAYERS, 2024
 
 
 
 
 
 
FIGURE 44
EV/EBITDA OF KEY VENDORS, 2025
 
 
 
 
 
 
FIGURE 45
YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS, 2025
 
 
 
 
 
 
FIGURE 46
IN VITRO DIAGNOSTICS MARKET: BRAND/PRODUCT COMPARISON
 
 
 
 
 
 
FIGURE 47
IN VITRO DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
 
 
 
 
 
 
FIGURE 48
IN VITRO DIAGNOSTICS MARKET: COMPANY FOOTPRINT
 
 
 
 
 
 
FIGURE 49
IN VITRO DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
 
 
 
 
 
 
FIGURE 50
DANAHER: COMPANY SNAPSHOT (2024)
 
 
 
 
 
 
FIGURE 51
F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2024)
 
 
 
 
 
 
FIGURE 52
ABBOTT: COMPANY SNAPSHOT (2024)
 
 
 
 
 
 
FIGURE 53
SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2024)
 
 
 
 
 
 
FIGURE 54
THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2024)
 
 
 
 
 
 
FIGURE 55
ILLUMINA, INC.: COMPANY SNAPSHOT (2024)
 
 
 
 
 
 
FIGURE 56
HOLOGIC, INC.: COMPANY SNAPSHOT (2024)
 
 
 
 
 
 
FIGURE 57
BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2024)
 
 
 
 
 
 
FIGURE 58
BIOMÉRIEUX: COMPANY SNAPSHOT (2024)
 
 
 
 
 
 
FIGURE 59
SYSMEX CORPORATION: COMPANY SNAPSHOT (2024)
 
 
 
 
 
 
FIGURE 60
REVVITY: COMPANY SNAPSHOT (2024)
 
 
 
 
 
 
FIGURE 61
BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2024)
 
 
 
 
 
 
FIGURE 62
AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2024)
 
 
 
 
 
 
FIGURE 63
QIAGEN: COMPANY SNAPSHOT (2024)
 
 
 
 
 
 
FIGURE 64
DIASORIN S.P.A: COMPANY SNAPSHOT (2023)
 
 
 
 
 
 
FIGURE 65
GRIFOLS, S.A.: COMPANY SNAPSHOT (2024)
 
 
 
 
 
 
FIGURE 66
WERFEN: COMPANY SNAPSHOT (2024)
 
 
 
 
 
 
FIGURE 67
QUIDELORTHO CORPORATION: COMPANY SNAPSHOT (2024)
 
 
 
 
 
 

Methodology

This study involved the extensive use of primary and secondary sources. A comprehensive study was conducted using secondary research methods to gather data about the market, its parent market, and its peer markets. The next stage involved conducting primary research to confirm these conclusions and assumptions and sizing with industry experts throughout the value chain. A combination of top-down and bottom-up methods was used to assess the overall market size. The market sizes of segments and subsegments were then estimated using data triangulation techniques and market breakdown.

Secondary Research

The secondary research process involves the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, investor presentations, SEC filings of companies and publications from government sources [such as National Institutes of Health (NIH), US FDA, US Census Bureau, World Health Organization (WHO), International Trade Administration (ITA), American Association for Clinical Chemistry (AACC), American Diabetes Association (ADA), Association for Molecular Pathology (AMP) and Centers for Medicare and Medicaid Services (CMS) were referred to identify and collect information for the global in vitro diagnostics market study. It was also used to obtain important information about the key players and market classification & segmentation according to industry trends to the bottom-most level and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

Primary Research

In the primary research process, various sources from the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations in the in vitro diagnostics market. The primary sources from the demand side include hospitals & clinics, clinical laboratories, blood banks, pharmaceutical and biotechnology companies, and academic institutes. Primary research was conducted to validate the market segmentation, identify key players, and gather insights on key industry trends & key market dynamics.

A breakdown of the primary respondents is provided below:

In Vitro Diagnostics Market

Note 1: C-level primaries include CEOs, CFOs, COOs, and VPs.

Note 2: Other designations include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.

Note 3: Tiers are defined based on a company’s total revenue. As of 2023, Tier 1= >USD 10 billion, Tier 2 = USD 1 billion to USD 10 billion, and Tier 3 = < USD 1 billion.

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

For the global market value, annual revenues were calculated based on the revenue mapping of major product manufacturers and OEMs active in the global in vitro diagnostics market. All the major product manufacturers were identified at the global and/or country/regional level. Revenue mapping for the respective business segments/subsegments was done for the major players. The global in vitro diagnostics market was split into various segments and sub-segments based on:

  • List of major players operating in the products market at the regional and/or country level.
  • Product mapping of various in vitro diagnostics manufacturers at the regional and/or country level.
  • Mapping of annual revenue generated by listed major players from in vitro diagnostics (or the nearest reported business unit/product category).
  • Extrapolation of the revenue mapping of the listed major players to derive the global market value of the respective segments/subsegments.
  • Summation of the market value of all segments/subsegments to arrive at the global in vitro diagnostics market.

The above-mentioned data was consolidated and added with detailed inputs and analysis from MarketsandMarkets and presented in this report.

Market Size Estimation (Bottom-up Approach & Top-down Approach)

In Vitro Diagnostics Market

Data Triangulation

After arriving at the overall size of the global in vitro diagnostics market through the above-mentioned methodology, this market was split into several segments and subsegments. Where applicable, the data triangulation and market breakdown procedures were employed to complete the overall market engineering process and arrive at the exact market value data for the key segments and subsegments. Examining several macro variables and regional trends from demand- and supply-side players helped triangulate the extrapolated market data.

Market Definition

IVD tests are non-invasive tests performed to diagnose, monitor, screen, and assess diseases and health conditions. The term "in vitro," which refers to "in glass," signifies that test tubes or petri dishes are typically used in these tests. These tests are performed artificially on biological samples (blood, urine, and tissues). IVD has a broad scope ranging from sophisticated technologies performed in clinical laboratories to simple and easy-to-use rapid testing kits.

IVD is used to assess a person's health. This technique is used in precision medicine to determine the suitable course of treatment for particular patients and diagnose and prevent diseases and other medical disorders.

Stakeholders

  • Transfection products manufacturing companies
  • Pharmaceutical & Biopharmaceutical Companies
  • Chemical Companies
  • Biopharmaceutical Companies
  • Contract Research Organizations (CROs)
  • Contract Development and Manufacturing Organizations (CDMOs)
  • Research Institutes and Universities 
  • Venture Capitalists & Investors
  • Government Associations

Report Objectives

  • To define, describe, and forecast the in vitro diagnostics (IVD) market based on product & service, technology, specimen, site of testing, application, end user, and region.
  • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and industry-specific challenges).
  • To assess the in vitro diagnostics market with respect to Porter’s Five Forces, regulatory landscape, the value chain, the supply chain, ecosystem analysis, patent protection, pricing assessment, key stakeholders, and buying criteria.
  • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market.
  • To analyze the opportunities in the IVD market for stakeholders and provide details of the competitive landscape for market leaders.
  • To forecast the size of the IVD market in six primary regions (along with countries)—North America, Europe, the Asia Pacific, Latin America, the Middle East & Africa, and the GCC Countries.
  • To profile the key players operating in the IVD market and comprehensively analyze their core competencies and market shares.
  • To track and analyze competitive developments such as partnerships, agreements, collaborations, acquisitions, expansions, product/technology developments, and product approvals.
  • To benchmark players within the IVD market using the Company Evaluation Quadrant framework, which analyzes market players on various parameters within categories of business strategies, market share, and product offerings.

 

TABLE OF CONTENTS

METHODOLOGY

Need a Tailored Report?

Customize this report to your needs

Get 10% FREE Customization

Customize This Report
Fact checked
Cite this Research

Adjacent Markets

Request Bundle Reports

Personalize This Research

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
Request A Free Customisation

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the In Vitro Diagnostics Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
Customized Workshop Request
Forbes

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Get 10% Free Customisation

Growth opportunities and latent adjacency in In Vitro Diagnostics Market

John

Jun, 2022

Who are the key companies/players in the in-vitro diagnostics market?.

James

Jun, 2022

What are some of the notable developments in the IVD market in recent years?.

Kahlill

Jun, 2022

What are the upcoming trends of In Vitro Diagnostics Market in the world?.

DMCA.com Protection Status